Delaware |
7370 |
98-1546280 | ||
(State or other Jurisdiction of Incorporation or Organization) |
(Primary Standard Industrial Classification Code Number) |
(I.R.S. Employer Identification Number) |
Large accelerated filer | ☐ | |
☒ | |||
Non-accelerated filer |
|
☐ |
Smaller reporting company | |||
Emerging growth company |
ii |
||||
1 |
||||
13 |
||||
16 |
||||
51 |
||||
52 |
||||
54 |
||||
61 |
||||
65 |
||||
70 |
||||
71 |
||||
85 |
||||
115 |
||||
125 |
||||
133 |
||||
134 |
||||
137 |
||||
142 |
||||
142 |
||||
142 |
||||
F-1 |
• |
our revenues, the concentration of our customers and the ability to retain our current customers; |
• |
our ability to negotiate with our customers on favorable terms; |
• |
our ability to maintain and grow our brand and reputation cost-effectively; |
• |
the execution of our growth strategy; |
• |
our projected financial information, growth rate and market opportunity; |
• |
the health of our industry, claim volumes, and market conditions; |
• |
changes in the insurance and automotive collision industries, including the adoption of new technologies; |
• |
global economic conditions and geopolitical events; |
• |
competition in our market and our ability to retain and grow market share; |
• |
our ability to develop, introduce and market new enhanced versions of our solutions and products; |
• |
our sales and implementation cycles; |
• |
the ability of our research and development efforts to create significant new revenue streams; |
• |
changes in applicable laws or regulations; |
• |
changes in international economic, political, social and governmental conditions and policies, including corruption risks in China and other countries; |
• |
currency fluctuations; |
• |
our reliance on third-party data, technology and intellectual property; |
• |
our ability to protect our intellectual property; |
• |
our ability to keep our data and information systems secure from data security breaches; |
• |
our ability to acquire or invest in companies or pursue business partnerships, which may divert our management’s attention or result in dilution to our stockholders, and we may be unable to integrate acquired businesses and technologies successfully or achieve the expected benefits of such acquisitions, investments or partnership; |
• |
our ability to raise financing in the future and improve our capital structure; |
• |
our success in retaining or recruiting, or changes required in, our officers, key employees or directors; |
• |
our officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business; |
• |
our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; |
• |
our financial performance; |
• |
our ability to expand or maintain its existing customer base; and |
• |
our ability to service our indebtedness. |
• | Vehicle parts proliferation: |
• | Internal technology systems: |
• | Growing connected car capabilities: |
• | Transportation as a Service (“TaaS”) and other new business models: |
• | Advanced Driver Assistance Systems (“ADAS”) and diagnostics systems: |
• | Vehicle Electrification and related infrastructure: 55-72 million by 2025 |
• | Multi-tenant cloud platform enabling flexibility and innovation: |
continuously enhance existing solutions and bring new solutions to market, deploying more than 1,700 software releases in 2021. |
• | Deep domain expertise: |
• | Long-term customer relationships: |
• | Network access: |
• | Proven R&D engine: |
• | Proprietary data assets: |
• | Enterprise scale and support: |
• | Growing our customer base: |
• | Deepening relationships with existing customers: up-selling customers based on package and feature upgrades. We intend to build upon strong customer relationships and access to key customer decision makers to increase software adoption and usage. |
• | Expanding the breadth of our solutions: Estimating-IQ for repair, Enterprise Payments, and more. |
• | Broadening our network ecosystem: |
• | Growing our geographic footprint: |
• | Pursuing acquisitions: |
• | CCC Workflow: end-to-end two-way text communications. Our workflow solutions leverage a sophisticated rules engine to customize routing for escalations, review, and approval processes. Our network management capability powers insurance DRPs, enabling |
insurers to seamlessly connect and collaborate with repair facilities and other companies to provide accurate and timely information about a claim flow from the right party at the right time. |
• | CCC Estimating: best-in-class |
• | CCC Total Loss: |
• | CCC AI and Analytics: AI-enabled solutions. All of our core software offerings are supported by Analytics solutions that allow our customers to benchmark and manage their business performance across key performance indicators. |
• | CCC Casualty: |
• | CCC Estimating: |
insurers and their corresponding requirements, which can accelerate estimate reviews and supplemental requests. Our Estimating-IQ upgrade incorporates AI into the repair estimating application to provide repairers with a jump start on estimating by applying machine learning to prepopulate estimates with parts and labor operations based on photos of vehicle damage and individual repair facility configurations. Our estimating solutions help reduce errors and improve cycle time for collision repairers and their partners. |
• | CCC Network Management: |
• | CCC Repair Workflow: Customer-to-shop |
• | CCC Repair Quality: |
• | CCC Parts Solutions: |
• | CCC Automotive Manufacturer Solutions: up-to-date |
repair facilities and technicians the tools to execute a proper repair. Our automotive telematics solutions enable new use cases across CCC’s integrated ecosystem, including connected safety and vehicle diagnostics solutions. Our telematics solutions integrate vehicle telemetry data, such as driving data, accident data, and diagnostics trouble codes, into existing insurance and repair workflows, expediting decisions and reducing cycle time across our ecosystem. Auto manufacturers also benefit from CCC Parts and Lender solutions, across their parts and financing businesses, respectively. |
• | CCC Lender Solutions: |
• | CCC Payments: |
• | Ease of implementation |
• | Flexibility |
insurers to design custom workflows that create differentiated experiences and adjust parameters to deliver targeted results. |
• | Innovation |
• | Security and Quality |
• | Availability and Uptime |
• | presenting only two years of audited financial statements and only two years of selected financial data; |
• | an exemption from compliance with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act; |
• | reduced disclosure about our executive compensation arrangements in our periodic reports, proxy statements, and registration statements; and |
• | exemptions from the requirements of holding nonbinding advisory votes on executive compensation or golden parachute arrangements. |
Shares of Common Stock to be issued upon exercise of all Warrants |
17,800,000 shares. |
Shares of Common Stock outstanding prior to the exercise of all Warrants |
614,720,075 shares. |
Use of proceeds |
We will receive up to an aggregate of approximately $204.7 million from the exercise of all Warrants assuming the exercise in full of all such Warrants for cash. Unless we inform you otherwise in a prospectus supplement or free writing prospectus, we intend to use the net proceeds from the exercise of such Warrants for general corporate purposes, which may include acquisitions, strategic investments, or repayment of outstanding indebtedness. |
Shares of Common Stock offered by the Selling Holders, consisting of (i) 17,800,000 shares of Common Stock underlying the Warrants and (ii) 523,199,737 shares of Common Stock |
540,999,737 shares. |
Warrants offered by the Selling Holders |
17,800,000 warrants. |
Exercise price |
$11.50 per share, subject to adjustment as described herein. |
Redemption |
The Warrants are redeemable in certain circumstances. See “Description of Securities—Private Placement Warrants” for further discussion. |
Use of proceeds |
We will not receive any proceeds from the sale of the Common Stock and Warrants to be offered by the Selling Holders. With respect to shares of Common Stock underlying the Warrants, we will not receive any proceeds from such shares except with respect to amounts received by us upon exercise of such Warrants to the extent such Warrants are exercised for cash. |
NYSE Ticker Symbol |
Common Stock: “CCCS” |
• | A substantial portion of our revenue is derived from a relatively small number of customers in the P&C insurance and automotive collision industries, and the loss of any of these customers, or a significant revenue reduction from any of these customers, could materially harm our business, results of operations and financial condition; |
• | Our business depends on our brand, and if we fail to develop, maintain, and enhance our brand and reputation cost-effectively, our business and financial condition may be adversely affected; |
• | Our revenue growth rate depends on existing customers renewing and upgrading their SaaS software subscriptions for our solutions. A decline in our customer renewals and expansions could adversely impact our future results of operations; |
• | Our growth strategy depends on continued investment in and delivery of innovative SaaS solutions. If we are unsuccessful in delivering innovative SaaS solutions, it could adversely impact our results of operations and financial condition; |
• | Public health outbreaks, epidemics or pandemics, including the global COVID-19 pandemic, could harm our business and results of operations; |
• | Macroeconomic factors impacting the principal industries we serve could adversely affect our product adoption, usage, or average selling prices; |
• | If we are unable to develop, introduce and market new and enhanced versions of our solutions and products, we may be put at a competitive disadvantage and our operating results could be adversely affected; |
• | Our sales and implementation cycles can be lengthy and variable, depend upon factors outside our control, and could cause us to expend significant time and resources prior to generating revenue; |
• | If we are unable to develop new markets or sell our solutions into these new and existing markets, our revenue will not grow as expected; |
• | Sales to customers or operations outside the United States may expose us to risks inherent in international sales; |
• | Changes in China’s economic, political or social conditions or government policies, as well as the corruption risks presented by operating in China, could have an adverse effect on our efforts to expand our business in China. |
• | We rely on data, technology and intellectual property of third parties and our solutions rely on information generated by third parties and any interruption of our access to such information, technology, and intellectual property could materially harm our operating results; |
• | Failure to protect our intellectual property could adversely impact our business and results of operations; |
• | Our solutions or products or our third-party cloud providers have experienced in the past, and could experience in the future, data security breaches, which could adversely impact our reputation, business, and ongoing operations; |
• | Some of our services and technologies use “open source” software, which may restrict how we use or distribute our services or require that we release the source code of certain products subject to those licenses; and |
• | We evaluate our capital structure from time to time and may seek to repurchase our securities, refinance our indebtedness or raise debt or equity to finance our operations. However, we may not be able to do so when desired on favorable terms, if at all, or without dilution to our stockholders and we may not realize the anticipated benefits of these transactions; and |
• | other risks and uncertainties indicated in this prospectus, including those set forth under the section entitled “Risk Factors.” |
• | compliance with multiple conflicting and changing governmental laws and regulations, including employment, tax, money transmission, privacy, and data protection laws and regulations; |
• | laws and business practices favoring local competitors; |
• | new and different sources of competition; |
• | securing new integrations for international technology platforms; |
• | localization of our solutions, including translation into foreign languages, obtaining and maintaining local content, and customer care in such languages; |
• | treatment of revenue from international sources and changes to tax rules, including being subject to foreign tax laws and liability for paying withholding or other taxes in foreign jurisdictions; |
• | fluctuation of foreign currency exchange rates; |
• | different pricing environments; |
• | restrictions on the transfer of funds; |
• | difficulties in staffing and managing foreign operations; |
• | availability of reliable internet connectivity in areas targeted for expansion; |
• | different or lesser protection of our intellectual property; |
• | longer sales cycles; |
• | natural disasters, acts of war, terrorism, pandemics, or security breaches; |
• | import and export license requirements, tariffs, taxes and other trade barriers; |
• | compliance with sanctions laws and regulations, including those administered by the Office of Foreign Assets Control (“OFAC”) of the U.S. Department of the Treasury; |
• | the burdens and costs of complying with a wide variety of foreign laws and legal standards, including the General Data Protection Regulation (EU 2016/679) (“GDPR”) in the European Union (“EU”); |
• | impact of Brexit on operations and growth of business in the European Union; |
• | compliance with various anti-bribery and anti-corruption laws such as the U.S. Foreign Corrupt Practices Act (“FCPA”); |
• | regional or national economic and political conditions; and |
• | pressure on the creditworthiness of sovereign nations resulting from liquidity issues or political actions. |
• | making it more difficult for us to make payments on outstanding principal and interest owed under the Credit Agreement; |
• | increasing our vulnerability to general economic and market conditions and to changes in the industries in which we compete; |
• | requiring a substantial portion of cash flow from operations to be dedicated to the payment of principal and interest owed under the Credit Agreement, thereby reducing our ability to use our cash flow to fund our operations, future working capital, capital expenditures, investments or acquisitions, future strategic business opportunities, or other general corporate requirements; |
• | restricting us from making acquisitions or causing us to make divestitures or similar transactions; |
• | limiting our ability to obtain additional financing for the purpose of funding working capital, capital expenditures, debt service requirements, investments, acquisitions, and general corporate purposes; |
• | limiting our ability to adjust to changing market conditions and placing us at a competitive disadvantage compared to our competitors who are less highly leveraged; and |
• | increasing our cost of borrowing. |
• | incur additional indebtedness; |
• | create or incur liens; |
• | pay dividends and distributions on, or purchase, redeem, defease, or otherwise acquire or retire for value, our capital stock; |
• | make repayments or repurchases of debt that is contractually subordinated with respect to right of payment or security; |
• | create negative pledges with respect to the Credit Facilities or restrictions on the payment of dividends or payment of other amounts owed from subsidiaries; |
• | make acquisitions, investments, loans (including guarantees), advance or capital contributions; |
• | engage in consolidations, amalgamations, mergers, liquidations, dissolutions, dispositions and/or sell, transfer, or otherwise dispose of assets, including capital stock of subsidiaries; |
• | enter into certain sale and leaseback transactions; |
• | engage in certain transactions with affiliates; |
• | change our material lines of business; |
• | modify certain documents governing certain debt that is subordinated with respect to right of payment; |
• | change our fiscal year; and |
• | conduct material operations at Cypress Intermediate Holdings II, Inc. |
• | changes in the industries in which we and our customers operate; |
• | variations in our operating performance and the performance of our competitors in general; |
• | material and adverse impact of the COVID-19 pandemic on the markets and the broader global economy; |
• | actual or anticipated fluctuations in our quarterly or annual operating results; |
• | publication of research reports by securities analysts about us or our competitors or industry; |
• | the public’s reaction to our press releases, other public announcements and filings with the SEC; |
• | our failure or the failure of our competitors to meet analysts’ projections or guidance that we or our competitors may give to the market; |
• | additions and departures of key personnel; |
• | changes in laws and regulations affecting our business; |
• | commencement of, or involvement in, litigation; |
• | changes in our capital structure, such as future issuances of securities or the incurrence of additional debt; |
• | the volume of shares of our Common Stock available for public sale; and |
• | general economic and political conditions such as recessions, interest rates, fuel prices, foreign currency fluctuations, international tariffs, social, political and economic risks and acts of war or terrorism. |
• | the ability of our Board to issue shares of preferred stock, including “blank check” preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer; |
• | the limitation of the liability of, and the indemnification of, our directors and officers; |
• | removal of the ability of our stockholders to take action by written consent in lieu of a meeting unless investment fund(s) affiliated with or managed by Advent International Corp. or any of its affiliates, or any successor, transferee or affiliate thereof, beneficially own a majority of the voting power of all of the then-outstanding shares of our capital stock entitled to vote on such action, or such action has been recommended or approved pursuant to a resolution approved by the affirmative vote of all of the directors then in office; |
• | the requirement that a special meeting of stockholders may be called only by a majority of our entire Board, which could delay the ability of stockholders to force consideration of a proposal or to take action, including the removal of directors; |
• | controlling the procedures for the conduct and scheduling of board of directors and stockholder meetings; |
• | the ability of the our Board to amend the bylaws, which may allow our Board to take additional actions to prevent an unsolicited takeover and inhibit the ability of an acquirer to amend the bylaws to facilitate an unsolicited takeover attempt; and |
• | advance notice procedures with which stockholders must comply to nominate candidates to our Board or to propose matters to be acted upon at a stockholders’ meeting, which could preclude stockholders from bringing matters before annual or special meetings of stockholders and delay changes in our Board, and also may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control of CCC. |
March 31, 2022 |
||||||||
Actual |
Pro Forma |
|||||||
Cash and Cash Equivalents |
195,497 | 400,197 | ||||||
Term B Loan—net of current portion and deferred financing fees |
778,996 | 778,996 | ||||||
Derivative warrant liabilities |
60,342 | — | ||||||
Preferred stock, $0.0001 par value, 1,000,000 shares authorized; none issued and outstanding, actual and as adjusted |
— | — | ||||||
Common stock, $0.0001 par value, 5,000,000,000 shares authorized; 613,758,126 shares issued and outstanding at March 31, 2022 |
61 | 63 | ||||||
Additional paid-in capital |
2,653,201 | 2,918,241 | ||||||
Accumulated deficit |
(734,377 | ) | (734,377 | ) | ||||
Cumulative Translation Adjustment |
(306 | ) | (306 | ) | ||||
|
|
|
|
|||||
Total stockholder’s equity |
1,918,579 | 2,183,621 | ||||||
|
|
|
|
|||||
Total capitalization |
2,757,917 | 3,158,114 | ||||||
|
|
|
|
• | the provisions regarding stockholder actions without a meeting; |
• | the provisions regarding calling special meetings of stockholders; |
• | the provisions regarding removal of directors; |
• | the provisions regarding the limited liability of directors of the Company; |
• | the provisions regarding competition and corporate opportunities; and |
• | the provisions regarding the election not to be governed by Section 203 of the DGCL. |
• | prior to such time, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; |
• | upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of our voting stock outstanding at the time the transaction commenced, excluding certain shares; or |
• | at or subsequent to that time, the business combination is approved by our board of directors and by the affirmative vote of holders of at least 66-2/3% of the outstanding voting stock that is not owned by the interested stockholder. |
• | each person known by us to be the beneficial owner of more than 5% of our outstanding Common Stock; |
• | each of our named executive officers and directors; and |
• | all of our executive officers and directors as a group. |
Name and Address of Beneficial Owners (1) |
Number of Shares |
% |
||||||
Githesh Ramamurthy (2) |
35,387,164 | 5.76 | % | |||||
Brian Herb (3) |
1,115,301 | * | ||||||
Barrett Callaghan (4) |
2,962,789 | * | ||||||
Steve G. Puccinelli |
— | — | ||||||
William Ingram (5) |
34,055 | * | ||||||
Eileen Schloss (6) |
102,164 | * | ||||||
Teri Williams (7) |
34,055 | * | ||||||
Christopher Egan |
— | — | ||||||
Eric Wei |
— | — | ||||||
Lauren Young |
— | — | ||||||
Name and Address of Beneficial Owners |
Number of Shares |
% |
||||||
All directors and executive officers (15 persons) (8) |
43,444,590 | 7.07 | % | |||||
Five Percent Holders: |
||||||||
Affiliates of Advent Investors (9) |
355,628,649 | 57.85 | % | |||||
OH Cypress Aggregator, L.P. (10) |
53,082,833 | 8.64 | % | |||||
TCV Investor (11) |
50,589,027 | 8.23 | % | |||||
Dragoneer Investment Group LLC (12) |
50,383,324 | 7.97 | % |
* | Less than 1% |
(1) | Unless otherwise noted, the business address of each of the directors and officers is 167 N. Green Street, 9th Floor, Chicago, Illinois 60607. The table excludes (i) the contingent right of Mr. Ramamurthy, Mr. Herb and Mr. Callaghan to receive an aggregate of up to 581,070, 38,632 and 81,748 shares based on the Company achieving certain trading price targets for its Common Stock or undergoing a change of control |
(“CCC Earnout Shares”), respectively and (ii) shares of Common Stock underlying performance restricted stock units, which represent a contingent right to receive a number of shares of Common Stock, cash or a combination thereof based on total shareholder return realized by stockholders over a specified period. |
(2) | Includes (i) 16,214,844 shares of the Common Stock and (ii) 19,172,320 shares of the Common Stock underlying stock options that are currently exercisable or that will become exercisable within 60 days of May 27, 2022. |
(3) | Includes (i) 340,550 shares of the Common Stock and (ii) 774,751 shares of the Common Stock underlying stock options that are currently exercisable or that will become exercisable within 60 days of May 27, 2022. |
(4) | Includes (i) 1,021,652 shares of the Common Stock and (ii) 1,941,137 shares of the Common Stock underlying stock options that are currently exercisable or that will become exercisable within 60 days of May 27, 2022. |
(5) | Represents 34,055 shares of Common Stock underlying stock options that are currently exercisable or that will become exercisable within 60 days of May 27, 2022. |
(6) | Represents 102,164 shares of Common Stock underlying stock options that are currently exercisable or that will become exercisable within 60 days of May 27, 2022. |
(7) | Represents 34,055 shares of Common Stock underlying stock options are currently exercisable or that will become exercisable within 60 days of May 27, 2022. |
(8) | Includes (i) 18,804,736 shares of Common Stock and (ii) 24,639,854 shares Common Stock underlying stock options that are currently exercisable or that will become exercisable within 60 days of May 27, 2022. |
(9) | Information based on an amendment to Schedule 13D filed by Advent International Corporation with the SEC on April 13, 2022. Cypress Investor Holdings, L.P. (“Cypress Investor”), Advent International GPE VIII-C Limited Partnership (“Advent International VIII-C”) GPE VIII CCC Co-Investment (Delaware) Limited Partnership (“GPE VIII CCC Co-Investment”) and Sunley House Capital Master Fund Limited Partnership (“Sunley House Master Fund”)) are the record holders of 260,498,239 shares, 8,238,944 shares 86,391,466 shares and 500,000 shares of the Common Stock, respectively. Cypress Investment GP, LLC (“Cypress GP”) is the general partner of Cypress Investor. Cypress Investor is beneficially owned by Advent International GPE VIII Limited Partnership (“Advent International VIII”), Advent International GPE VIII-A Limited Partnership (“Advent International VIII-A”), Advent International GPE VIII-B-1 Limited Partnership (“Advent International VIII-B-1”), Advent International GPE VIII-B-2 Limited Partnership (“Advent International VIII-B-2”), Advent International GPE VIII-B-3 Limited Partnership (“Advent International VIII-B-3”), Advent International GPE VIII-B Limited Partnership (“Advent International VIII-B”), Advent International GPE VIII-D Limited Partnership (“Advent International VIII-D”), Advent International GPE VIII-E Limited Partnership (“Advent International VIII-E”), Advent International GPE VIII-F Limited Partnership (“Advent International VIII-F”), Advent International GPE VIII-G Limited Partnership (“Advent International VIII-G”), Advent International GPE VIII-H Limited Partnership (“Advent International VIII-H”), Advent International GPE VIII-I Limited Partnership (“Advent International VIII-I”), Advent International GPE VIII-J Limited Partnership (“Advent International VIII-J” and together with Advent International VIII, Advent International VIII-B-1, Advent International VIII-B-2, Advent International VIII-B-3, Advent International VIII-B, Advent International VIII-D, Advent International VIII-F, Advent International VIII-H and Advent International VIII-I, the “Advent Luxembourg Funds”), Advent International GPE VIII-K Limited Partnership (“Advent International VIII-K”), Advent International GPE VIII-L Limited Partnership (“Advent International VIII-L” and together with Advent International VIII-A, Advent International VIII-E, Advent International VIII-G and Advent International VIII-K, the “Advent Cayman Funds”), Advent Partners GPE VIII Limited Partnership (“Advent Partners VIII”), Advent Partners GPE VIII-A Limited Partnership (“Advent Partners VIII-A”), Advent Partners GPE VIII Cayman Limited Partnership (“Advent Partners VIII Cayman”), Advent Partners GPE VIII-A Cayman Limited Partnership (“Advent Partners VIII-A Cayman”) and Advent Partners GPE VIII-B Cayman Limited Partnership (“Advent Partners VIII-B Cayman” and together with Advent Partners VIII, Advent Partners VIII-A, Advent Partners VIII Cayman and Advent Partners VIII-A Cayman, the “Advent Partners Funds”). The Advent Luxembourg Funds, the Advent Cayman Funds and the Advent Partners Funds have ownership interests in Cypress Investor, but none of the Advent Luxembourg Funds, the Advent Cayman Funds or the Advent Partners Funds has voting or dispositive power over any shares. GPE VIII GP S.à r.l. is the general |
partner the of Advent Luxembourg Funds and Advent International VIII-C. GPE VIII GP Limited Partnership is the general partner of the Advent Cayman Funds, and GPE VIII CCC Co-Investment. AP GPE VIII GP Limited Partnership is the general partner of the Advent Partners Funds. Advent International GPE VIII, LLC is the manager of GPE VIII GP S.à r.l. and the general partner of each of GPE VIII GP Limited Partnership and AP GPE VIII GP Limited Partnership. Sunley House Capital GP LP (“Sunley House GP LP”), as general partner of Sunley House Master Fund, Sunley House Capital GP LLC (“Sunley House GP LLC”), as general partner of Sunley House GP LP, and Sunley House Capital Management LLC (“Sunley House Manager”), as investment manager to Sunley House Master Fund, may be deemed to beneficially own the shares held directly by Sunley House Master Fund. Advent International Corporation is the managing member of Cypress GP, the manager of Advent International GPE VIII, LLC and the sole member of both Sunley House GP LLC and Sunley House Manager. Investors in the Sunley House Master Fund invest in one or more of the following feeder funds: Sunley House Capital Fund LP, Sunley House Capital Limited Partnership, Sunley House Capital Fund Ltd. and Sunley House Capital Ltd. (collectively, the “Sunley House Feeder Funds”), which are the limited partners of the Sunley House Master Fund. The Sunley House Feeder Funds have ownership interests in the Sunley House Master Fund, but none of the Sunley House Feeder Funds owns shares directly and none has voting or dispositive power over the shares held directly by the Sunley House Master Fund. The foregoing excludes the contingent right of Cypress Investor, Advent International VIII-C and GPE VIII CCC Co-Investment to receive an aggregate of up to 9,919,012 CCC Earnout Shares. Voting and investment decisions by Advent International Corporation are made by a number of individuals currently comprised of John L. Maldonado, David M. McKenna and David M. Mussafer. The address of each of the entities and individuals named in this footnote is c/o Advent International Corporation, Prudential Tower, 800 Boylston St., Suite 3300, Boston, MA 02199. |
(10) | Information based on an amendment to Schedule 13D filed by OH Cypress Aggregator, L.P. with the SEC on August 9, 2021. OH Cypress Aggregator, L.P. is beneficially owned by Oak Hill Capital Partners IV (Onshore), L.P., Oak Hill Capital Partners IV (Onshore Tax Exempt), L.P., Oak Hill Capital Partners IV (Offshore), L.P., Oak Hill Capital Partners IV (Offshore 892), L.P., Oak Hill Capital Partners IV (Management), L.P. (together, including OH Cypress Aggregator, the “Oak Hill Fund IV Entities”) and certain of their co-investors. The general partner of each of the Oak Hill Fund IV Entities is OHCP GenPar IV, L.P. (the “Oak Hill GP”). The general partner of Oak Hill GP is OHCP MGP IV, Ltd. (the “Oak Hill UGP”). The foregoing excludes the contingent right of OH Cypress Aggregator, L.P. to receive an aggregate of up to 1,412,990 CCC Earnout Shares. The three managing partners of Oak Hill, Tyler Wolfram, Brian Cherry and Steven Puccinelli, serve as the directors of the Oak Hill UGP and may be deemed to exercise voting and investment control over the shares held by the Oak Hill Fund IV Entities. The address for these entities is 65 East 55th Street, 32nd Floor, New York, NY 10022. |
(11) | Information based on an amendment to Schedule 13D filed by Technology Crossover Management IX, Ltd. with the SEC on August 9, 2021. The general partner of TCV Member Fund, L.P. (the “Member Fund”) is Technology Crossover Management IX, Ltd. (“Management IX”), and the general partner of each of TCV IX, L.P., TCV IX (A), L.P., and TCV IX (B), L.P. (together with the Member Fund, the “TCV IX Funds”) is Technology Crossover Management IX, L.P. (“TCM IX”). The general partner of TCM IX is Management IX. Management IX and TCM IX may be deemed to beneficially own the securities held by the TCV IX Funds directly or indirectly controlled by them, but each disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein. The foregoing excludes the contingent right of the TCV Investor to receive an aggregate of up to 1,412,988 CCC Earnout Shares. Jay C. Hoag, Jon Q. Reynolds Jr., Timothy P. McAdam and Christopher P. Marshall are the Class A Directors of Management IX, and each disclaims beneficial ownership of the securities held by the TCV IX Funds except to the extent of his pecuniary interest therein. The address of the entities named in this footnote is 250 Middlefield Road, Menlo Park, CA 94025. |
(12) | Information based on an amendment to Schedule 13G filed by Dragoneer Investment Group, LLC (“Dragoneer Advisor”) with the SEC on February 14, 2022. Consists of (i) 17,800,000 shares of warrants to purchase Common Stock and (ii) 32,583,324 shares of Common Stock. Dragoneer Funding I LLC directly holds 32,572,716 shares of Common Stock and warrants exercisable for 17,800,000 Common Stock. Dragoneer Funding LLC directly holds 10,608 shares of Common Stock. Dragoneer Adviser is the |
investment adviser to certain funds that hold membership interests in Dragoneer Funding I LLC and Dragoneer Funding LLC. Dragoneer Funding I, LLC is controlled by Marc Stad. Mr. Stad may be deemed to share voting and dispositive power with respect to the securities held by such entity. The business address of Dragoneer Advisor and Mr. Stad is c/o Dragoneer Investment Group, LLC, One Letterman Drive, Building D, Suite M500, San Francisco, California. |
Securities Beneficially Owned Prior to This Offering |
Securities to be Sold in This Offering |
Securities Beneficially Owned After This Offering |
||||||||||||||||||||||||||||||
Shares of Common Stock (1) |
Warrants (2) |
Shares of Common Stock (1) |
Warrants (2) |
Shares of Common Stock (1) |
% |
Warrants (2) |
% |
|||||||||||||||||||||||||
Affiliates of Advent Investors (3) |
355,628,649 | — | 355,628,649 | — | — | — | — | — | ||||||||||||||||||||||||
OH Cypress Aggregator, L.P. (4) |
53,082,833 | — | 53,082,833 | — | — | — | — | — | ||||||||||||||||||||||||
TCV Investors (5) |
50,589,027 | — | 50,589,027 | — | — | — | — | — | ||||||||||||||||||||||||
Dragoneer Investment Group LLC (6) |
50,383,324 | 17,800,000 | 50,383,324 | 17,800,000 | — | — | — | — | ||||||||||||||||||||||||
Affiliates of Willett Advisors (7) |
2,866,284 | — | 2,866,284 | — | — | — | — | — | ||||||||||||||||||||||||
Githesh Ramamurthy |
16,214,844 | — | 16,214,844 | — | — | — | — | — | ||||||||||||||||||||||||
Barrett Callaghan |
1,021,652 | — | 1,021,652 | — | — | — | — | — | ||||||||||||||||||||||||
Marc Fredman |
374,605 | — | 374,605 | — | — | — | — | — | ||||||||||||||||||||||||
Brian Herb |
340,550 | — | 340,550 | — | — | — | — | — |
Securities Beneficially Owned Prior to This Offering |
Securities to be Sold in This Offering |
Securities Beneficially Owned After This Offering |
||||||||||||||||||||||||||||||
Shares of Common Stock (1) |
Warrants (2) |
Shares of Common Stock (1) |
Warrants (2) |
Shares of Common Stock (1) |
% |
Warrants (2) |
% |
|||||||||||||||||||||||||
Mary Jo Prigge |
853,085 | — | 853,085 | — | — | — | — | — | ||||||||||||||||||||||||
Funds associated with Capital Research and Management Company (9) |
13,376,908 | — | 4,000,000 | — | 9,376,908 | 1.5 | % | — | — | |||||||||||||||||||||||
Affiliates of Fidelity (11) |
926,055 | — | 926,055 | — | — | — | — | — | ||||||||||||||||||||||||
Affiliates of Janus Henderson (12) |
1,000,000 | — | 1,000,000 | — | — | — | — | — | ||||||||||||||||||||||||
Affiliates of MFS Investment Management (13) |
3,900,643 | — | 500,000 | — | 3,400,643 | * | — | — | ||||||||||||||||||||||||
Affiliates of T.Rowe Price (14) |
2,493,829 | — | 2,493,829 | — | — | — | — | — | ||||||||||||||||||||||||
Affiliates of Maverick Capital (15) |
3,137,836 | — | 500,000 | — | 2,637,836 | * | — | — | ||||||||||||||||||||||||
Additional selling securityholders (16) |
225,000 | — | 225,000 | — | — | — | — | — | ||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
TOTAL |
556,415,124 | 17,800,00 | 540,999,737 | 17,800,00 | 15,415,387 | 2.5 | % | — | — | |||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* | Represents less than 1%. |
(1) | Represents shares of Common Stock, including the shares of Common Stock that may be issued upon the exercise of Warrants. |
(2) | Represents the Private Placement Warrants. |
(3) | Cypress Investor Holdings, L.P. (“Cypress Investor”), Advent International GPE VIII-C Limited Partnership (“Advent International VIII-C”) GPE VIII CCC Co-Investment (Delaware) Limited Partnership (“GPE VIII CCC Co-Investment”) and Sunley House Capital Master Fund Limited Partnership (“Sunley House Master Fund”) are the record holders of 260,498,239 shares, 8,238,944 shares 86,391,466 shares and 500,000 shares of the Common Stock, respectively. Cypress Investment GP, LLC (“Cypress GP”) is the general partner of Cypress Investor. Cypress Investor is beneficially owned by Advent International GPE VIII Limited Partnership (“Advent International VIII”), Advent International GPE VIII-A Limited Partnership (“Advent International VIII-A”), Advent International GPE VIII-B-1 VIII-B-1”), VIII-B-2 VIII-B-2”), VIII-B-3 VIII-B-3”), VIII-B Limited Partnership (“Advent International VIII-B”), Advent International GPE VIII-D Limited Partnership (“Advent International VIII-D”), Advent International GPE VIII-E Limited Partnership (“Advent International VIII-E”), Advent International GPE VIII-F Limited Partnership (“Advent International VIII-F”), Advent International GPE VIII-G Limited Partnership (“Advent International VIII-G”), Advent International GPE VIII-H Limited Partnership (“Advent International VIII-H”), Advent International GPE VIII-I Limited Partnership (“Advent International VIII-I”), Advent International GPE VIII-J Limited Partnership (“Advent International VIII-J” and together with Advent International VIII, Advent International VIII-B-1, VIII-B-2, VIII-B-3, VIII-B, Advent International VIII-D, Advent International VIII-F, Advent International VIII-H and Advent International VIII-I, the “Advent Luxembourg Funds”), Advent International GPE VIII-K Limited Partnership (“Advent International VIII-K”), Advent International GPE VIII-L Limited Partnership (“Advent International VIII-L” and together with Advent International VIII-A, Advent International VIII-E, Advent International VIII-G and Advent International VIII-K, the “Advent Cayman Funds”), Advent Partners GPE VIII Limited Partnership (“Advent Partners VIII”), Advent Partners GPE VIII-A Limited Partnership (“Advent Partners VIII-A”), Advent Partners GPE VIII Cayman Limited Partnership (“Advent Partners VIII Cayman”), Advent Partners GPE VIII-A Cayman Limited Partnership (“Advent Partners VIII-A Cayman”) and Advent Partners GPE VIII-B Cayman Limited Partnership (“Advent Partners VIII-B Cayman” and together with Advent Partners VIII, Advent Partners VIII-A, Advent Partners VIII Cayman and Advent Partners VIII-A Cayman, the “Advent Partners Funds”). The Advent Luxembourg Funds, the Advent Cayman Funds and the Advent Partners Funds have ownership interests in Cypress Investor, but none of the Advent Luxembourg Funds, the Advent Cayman Funds or the Advent Partners Funds has voting or dispositive power over any shares. GPE VIII GP S.à r.l. is the general partner the of Advent Luxembourg Funds and Advent International VIII-C. GPE VIII GP Limited Partnership is the general partner of the Advent Cayman Funds, and GPE VIII CCC Co-Investment. AP GPE VIII GP Limited Partnership is the general partner of the Advent Partners Funds. Advent International GPE VIII, LLC is the manager of GPE VIII GP S.à r.l. and the general partner of each of GPE VIII GP Limited Partnership and AP GPE VIII GP Limited Partnership. Sunley House Capital GP LP (“Sunley House GP LP”), as general partner of Sunley House Master Fund, Sunley House Capital GP LLC (“Sunley House GP LLC”), as general partner of Sunley House GP LP, and Sunley |
House Capital Management LLC (“Sunley House Manager”), as investment manager to Sunley House Master Fund, may be deemed to beneficially own the shares held directly by Sunley House Master Fund. Advent International Corporation is the managing member of Cypress GP, the manager of Advent International GPE VIII, LLC and VIII-C and GPE VIII CCC Co-Investment to receive an aggregate of up to 9,919,012 CCC Earnout Shares. Voting and investment decisions by Advent International Corporation are made by a number of individuals currently comprised of John L. Maldonado, David M. McKenna and David M. Mussafer. The address of each of the entities and individuals named in this footnote is c/o Advent International Corporation, Prudential Tower, 800 Boylston St., Suite 3300, Boston, MA 02199. |
(4) | OH Cypress Aggregator, L.P. is beneficially owned by Oak Hill Capital Partners IV (Onshore), L.P., Oak Hill Capital Partners IV (Onshore Tax Exempt), L.P., Oak Hill Capital Partners IV (Offshore), L.P., Oak Hill Capital Partners IV (Offshore 892), L.P., Oak Hill Capital Partners IV (Management), L.P. (together, including OH Cypress Aggregator, the “Oak Hill Fund IV Entities”) and certain of their co-investors. The general partner of each of the Oak Hill Fund IV Entities is OHCP GenPar IV, L.P. (the “Oak Hill GP”). The general partner of Oak Hill GP is OHCP MGP IV, Ltd. (the “Oak Hill UGP”). The foregoing excludes the contingent right of OH Cypress Aggregator, L.P. to receive an aggregate of up to 1,412,990 CCC Earnout Shares. The three managing partners of Oak Hill, Tyler Wolfram, Brian Cherry and Steven Puccinelli, serve as the directors of the Oak Hill UGP and may be deemed to exercise voting and investment control over the shares held by the Oak Hill Fund IV Entities. The address for these entities is 65 East 55th Street, 32nd Floor, New York, NY 10022. |
(5) | The general partner of TCV Member Fund, L.P. (the “Member Fund”) is Technology Crossover Management IX, Ltd. (“Management IX”), and the general partner of each of TCV IX, L.P., TCV IX (A), L.P., and TCV IX (B), L.P. (together with the Member Fund, the “TCV IX Funds”) is Technology Crossover Management IX, L.P. (“TCM IX”). The general partner of TCM IX is Management IX. Management IX and TCM IX may be deemed to beneficially own the securities held by the TCV IX Funds directly or indirectly controlled by them, but each disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein. The foregoing excludes the contingent right of the TCV Investor to receive an aggregate of up to 1,412,988 CCC Earnout Shares. Jay C. Hoag, Jon Q. Reynolds Jr., Timothy P. McAdam and Christopher P. Marshall are the Class A Directors of Management IX, and each disclaims beneficial ownership of the securities held by the TCV IX Funds except to the extent of his pecuniary interest therein. The address of the entities named in this footnote is 250 Middlefield Road, Menlo Park, CA 94025. |
(6) | Consists of (a) 17,800,000 warrants to purchase Common Stock held by Dragoneer Funding I LLC, (b) 32,572,716 shares of Common Stock held by Dragoneer Funding I LLC and (c) 10,608 shares of Common Stock held by Dragoneer Funding LLC. Shares of Common Stock are inclusive of the share of Common Stock issuable upon exercise of Dragoneer Funding I LLC’s warrants. The ultimate managing member of Dragoneer Funding I, LLC and Dragoneer Funding LLC is controlled by Marc Stad and he may be deemed to share voting and dispositive power with respect to the securities held by such entity. The business address of Dragoneer Funding I LLC and Mr. Stad is c/o Dragoneer Investment Group, LLC, One Letterman Drive, Building D, Suite M500, San Francisco, California. |
(7) | Represents (a) 286,628 shares of Common Stock held by Silas Holdings LLC, (b) 232,169 shares of Common Stock held by 63019 Holdings LLC, (c) 257,965 shares of Common Stock held by Willett Private Investors I LP and (d) 2,089,522 shares of Common Stock held by Willett Private Investors I LP (Tax Exempt). The business address of each of the affiliates of Willett Advisors other than Silas Holdings I LLC is c/o Willett Advisors LLC, 650 Madison Avenue, 17th Floor, New York, NY 10022. The business address of Silas Holdings I LLC is c/o Rattner Family Office, 650 Madison Avenue, 17th Floor, New York, NY 10022. |
(8) | Represents the working capital warrants that were issued upon conversion of the principal amount of a working capital loan provided by Sponsor to Dragoneer, which conversion occurred upon the consummation of the Business Combination. The ultimate managing member of Sponsor is controlled by Marc Stad and he may be deemed to share voting and dispositive power with respect to the securities held by such entity. The business address of Sponsor and Mr. Stad is c/o Dragoneer Investment Group, LLC, One Letterman Drive, Building D, Suite M500, San Francisco, California. |
(9) | Consists of shares of Common Stock acquired in the PIPE Financing and purchased on the open market. Consists of 6,953,198 shares held by SMALLCAP World Fund, Inc. Julian N. Abdey, Michael Beckwith, Peter Eliot, Brady L. Enright. Bradford F. Freer, Leo Hee, Roz Hongsaranagon, Jonathan Knowles, Harold H. La, Shlok Melwani, Dimitrije M. Mitrinovic, Aidan O’Connell, Samir Parekh, Andraz Razen, Renaud H. Samyn, Arun Swaminathan, Thatcher |
Thompson and Gregory W. Wendt, as portfolio managers, have voting and investment power over the securities held by SMALLCAP World Fund, Inc. Consists of 2,467,640 shares of Common Stock held by The New Economy Fund. Timothy D. Armour, Mathews Cherian, Tomoko Fortune, Caroline Jones, Harold H. La, Reed Lowenstein, Lara Pellini and Richmond Wolf, as portfolio managers, have voting and investment power over the securities held by The New Economy Fund. Consists of 1,727,177 shares held by AMCAP Fund. Cheryl E. Frank, Martin Jacobs, Aidan O’Connell, Lawrence R. Solomon, Jessica C. Spaly, Eric H. Stern, James Terrile and Gregory W. Wendt, as portfolio managers, have voting and investment power over the securities held by AMCAP Fund. Consists of 1,480,590 shares held by The Growth Fund of America. Julian N. Abdey, Christopher D. Buchbinder, Mark L. Casey, J. Blair Frank, Joanna F. Jonsson, Carl M. Kawaja, Donald D. O’Neal, Anne-Marie Peterson, Alex Popa, Andraz Razen, Martin Romo, Lawrence R. Solomon and Alan J. Wilson, as portfolio managers, have voting and investment power over the securities held by The Growth Fund of America. Consists of 644,074 shares held by American Funds Insurance Series - Global Small Capitalization Fund. Michael Beckwith, Bradford F. Freer, Harold H. La, Aidan O’Connell, Renaud H. Samyn and Gregory W. Wendt, as portfolio managers, have voting and investment power over the securities held by American Funds Insurance Series - Global Small Capitalization Fund. Consists of 43,705 shares of Common Stock held by Capital Group New Economy Fund (LUX). Timothy D. Armour, Mathews Cherian, Tomoko Fortune, Caroline Jones, Harold H. La, Reed Lowenstein, Lara Pellini and Richmond Wolf, as portfolio managers, have voting and investment power over the securities held by Capital Group New Economy Fund (LUX). Consists of 31,740 shares of Common Stock held by Capital Group New Economy Trust (US). Timothy D. Armour, Mathews Cherian, Tomoko Fortune, Caroline Jones, Harold H. La, Reed Lowenstein, Lara Pellini and Richmond Wolf, as portfolio managers, have voting and investment power over the securities held by Capital Group New Economy Trust (US). Consists of 14,723 shares held by Capital Group AMCAP Trust (US). Cheryl E. Frank, Martin Jacobs, Aidan O’Connell, Lawrence R. Solomon, Jessica C. Spaly, Eric H. Stern, James Terrile and Gregory W. Wendt, as portfolio managers, have voting and investment power over the securities held by Capital Group AMCAP Trust (US). Consists of 10,520 shares of Common Stock held by Capital Group Growth Fund of America Trust (US). Julian N. Abdey, Christopher D. Buchbinder, Mark L. Casey, J. Blair Frank, Joanna F. Jonsson, Carl M. Kawaja, Donald D. O’Neal, Anne-Marie Peterson, Alex Popa, Andraz Razen, Martin Romo, Lawrence R. Solomon and Alan J. Wilson, as portfolio managers, have voting and investment power over the securities held by Capital Group Growth Fund of America Trust (US). Consists of 3,541 shares held by Capital Group AMCAP Fund (LUX). Cheryl E. Frank, Martin Jacobs, Aidan O’Connell, Lawrence R. Solomon, Jessica C. Spaly, Eric H. Stern, James Terrile and Gregory W. Wendt, as portfolio managers, have voting and investment power over the securities held by Capital Group AMCAP Fund (LUX). Capital Research and Management Company is the investment adviser for each of the funds associated with Capital Research and Management Company. The business address of each of the funds associated with Capital Research and Management Company is 333 S. Hope Street, 55th Floor, Los Angeles, CA 90071. |
(10) | Represents shares of Common Stock acquired by Coatue FinTech Fund I LP in the PIPE Financing. Coatue FinTech Fund I LP is managed by Coatue Management, L.L.C. The sole owner of Coatue Management, L.L.C. is Coatue Management Partners LP, for which Coatue Management Partners GP LLC serves as general partner. Mr. Philippe Laffont serves as managing member of Coatue Management Partners GP LLC. Mr. Laffont and Coatue Management, L.L.C. disclaim beneficial ownership of the shares held by Coatue FinTech Fund I LP except to the extent of their pecuniary interest therein. The business address for Mr. Laffont, Coatue Management, L.L.C. and Coatue FinTech Fund I LP is 9 West 57th Street, 25th Floor, New York, NY 10019. |
(11) | Represents shares of Common Stock acquired in the PIPE Financing. Represents (a) 26,636 shares of Common Stock held of record by Variable Insurance Products Fund III: VIP Growth Opportunities Portfolio, (b) 180,037 shares of Common Stock held of record by Fidelity Advisor Series I: Fidelity Advisor Growth Opportunities Fund, (c) 6,302 shares of Common Stock held of record by Fidelity Advisor Series I: Fidelity Advisor Series Growth Opportunities Fund, (d) 2,248 shares of Common Stock held of record by Fidelity U.S. Growth Opportunities Investment Trust, by its manager Fidelity Investments Canada ULC, (e) 22,661 shares of Common Stock held of record by Fidelity NorthStar Fund—Sub D, by its manager Fidelity Investments Canada ULC, (f) 36,613 shares of Common Stock held of record by Variable Insurance Products Fund III: VIP Balanced Portfolio—Information Technology Sub, (g) 34,443 shares of Common Stock held of record by Fidelity Advisor Series I: Fidelity Advisor Balanced Fund—Information Technology Sub, (h) 3,671 shares of Common Stock held of record by Fidelity Puritan Trust: Fidelity Balanced K6 Fund—Information Technology Sub-portfolio, (i) 253,848 shares of Common Stock held of record by Fidelity Puritan Trust: Fidelity Balanced Fund—Information Technology Sub, (j) 102,045 shares of Common Stock held of record by Fidelity Select Portfolios: Select Technology Portfolio, (k) 134,385 shares of Common Stock held of record by Strategic Advisers Fidelity U.S. Total Stock Fund—FIAM Sector Managed—Technology Sub, (l) 35,655 shares of Common Stock held of record by Strategic Advisers Large Cap Fund—FIAM Sector Managed Technology Sub, by FIAM LLC as Investment Manager , (m) 27,668 shares of Common Stock held of record by Fidelity Trend Fund: Fidelity Trend Fund, (n) 48,511 shares of Common Stock held of record by Fidelity Securities Fund: Fidelity Small Cap Growth Fund, (o) 10,832 shares |
of Common Stock held of record by Fidelity Securities Fund: Fidelity Small Cap Growth K6 Fund and (p) 500 shares of Common Stock held of record by Fidelity Capital Trust: Fidelity Flex Small Cap Fund—Small Cap Growth Subportfolio. The business address of each of the affiliates of Fidelity is 245 Summer Street, Boston, MA 02110. |
(12) | Represents shares of Common Stock acquired in the PIPE Financing. Represents (a) 112,363 shares of Common Stock held of record by BNP Paribas New York Branch on behalf of Janus Henderson Global Technology and Innovation Portfolio and (b) 887,637 shares of Common Stock held of record by BNP Paribas New York Branch on behalf of Janus Henderson Global Technology and Innovation Fund. Based on information provided to the Company by the Selling Stockholder. Such shares may be deemed to be beneficially owned by Janus Henderson Investors US LLC (“Janus”), an investment adviser registered under the Investment Advisers Act of 1940, who acts as investment adviser for the Fund and has the ability to make decisions with respect to the voting and disposition of the shares subject to the oversight of the board of directors of the Fund. Under the terms of its management contract with the Fund, Janus has overall responsibility for directing the investments of the Fund in accordance with the Fund’s investment objective, policies and limitations. Each Fund has one or more portfolio managers appointed by and serving at the pleasure of Janus who makes decisions with respect to the disposition of the Shares. The address for Janus is 151 Detroit Street, Denver, CO 80206. The portfolio managers for these funds are: Denny Fish and Jonathan Cofsky. |
(13) | Includes 500,000 shares of Common Stock acquired in the PIPE Financing. Represents (a) 3,605,340 shares of Common Stock held of record by MFS Mid Cap Growth Fund (including 452,972 shares of Common Stock acquired in the PIPE Financing), (b) 23,134 shares of Common Stock held of record by AST MFS Growth Allocation Portfolio (including 3,396 shares of Common Stock acquired in the PIPE Financing), (c) 178,646 shares of Common Stock held of record by AST Mid-Cap Growth Portfolio (including 29,748 shares of Common Stock acquired in the PIPE Financing) and (d) 93,523 shares of Common Stock held of record by MFS Variable Insurance Trust - MFS Mid Cap Growth Series (including 13,884 shares of Common Stock acquired in the PIPE Financing). The business address of each of the affiliates of MFS Investment Management is c/o MFS Investment Management, 111 Huntington Ave, Boston, MA 02199-7618. |
(14) | Represents shares of Common Stock acquired in the PIPE Financing. Represents (a) 1,273,239 shares of Common Stock held of record by T. Rowe Price Mid-Cap Growth Fund, Inc., (b) 260,346 shares of Common Stock held of record by T. Rowe Price Institutional Mid-Cap Equity Growth Fund, (c) 20,220 shares of Common Stock held of record by T. Rowe Price Mid-Cap Growth Portfolio, (d) 8,276 shares of Common Stock held of record by T. Rowe Price U.S. Equities Trust, (e) 66,127 shares of Common Stock held of record by Great-West Funds, Inc.—Great-West T. Rowe Price Mid Cap Growth Fund, (f) 90,991 shares of Common Stock held of record by TD Mutual Funds—TD U.S. Mid-Cap Growth Fund, (g) 241,702 shares of Common Stock held of record by MassMutual Select Funds—MassMutual Select Mid Cap Growth Fund, (h) 13,156 shares of Common Stock held of record by MML Series Investment Fund—MML Mid Cap Growth Fund, (i) 60,461 shares of Common Stock held of record by Brighthouse Funds Trust I—T. Rowe Price Mid Cap Growth Portfolio, (j) 21,566 shares of Common Stock held of record by Marriott International, Inc. Pooled Investment Trust for Participant Directed Accounts, (k) 183,731 shares of Common Stock held of record by T. Rowe Price U.S. Mid-Cap Growth Equity Trust, (l) 48,232 shares of Common Stock held of record by Costco 401(k) Retirement Plan, (m) 8,082 shares of Common Stock held of record by MassMutual Select Funds—MassMutual Select T. Rowe Price Small and Mid Cap Blend Fund, (n) 77,629 shares of Common Stock held of record by T. Rowe Price Diversified Mid-Cap Growth Fund, Inc., (o) 9,114 shares of Common Stock held of record by The Bunting Family III, LLC, (p) 2,683 shares of Common Stock held of record by Seasons Series Trust—SA Multi-Managed Mid Cap Growth Portfolio, (q) 40,350 shares of Common Stock held of record by Lincoln Variable Insurance Products Trust—LVIP T. Rowe Price Structured Mid-Cap Growth Fund, (r) 46,036 shares of Common Stock held of record by Voya Partners, Inc.—VY T. Rowe Price Diversified Mid Cap Growth Portfolio, (s) 6,257 shares of Common Stock held of record by T. Rowe Price Tax-Efficient Equity Fund, (t) 14,369 shares of Common Stock held of record by Lincoln Variable Insurance Products Trust—LVIP Blended Mid Cap Managed Volatility Fund and (u) 1,262 shares of Common Stock held of record by Jeffrey LLC. The business address of each of the affiliates of T. Rowe Price is c/o T. Rowe Price Associates, Inc., 100 East Pratt Street, Baltimore, MD 21202. |
(15) | As of March 31, 2022. Based on a Form 13F filed by Maverick Capital Ltd. (“Maverick Capital”) on May 16, 2022. Maverick Capital is an investment adviser registered as such with the Securities and Exchange Commission and, as such, may be deemed to have beneficial ownership of the shares of Common Stock through the investment discretion it exercises over the accounts of its clients, the holders of record of the shares of Common Stock. The business address of each of the affiliates of Maverick Capital is c/o Maverick Capital, Ltd., 1900 N. Pearl Street, 20th Floor, Dallas, TX 75201. |
(16) | The disclosure with respect to the remaining selling securityholders is being made on an aggregate basis, as opposed to an individual basis, because their aggregate holdings are less than 1% of the outstanding shares of our Common Stock. Represents an aggregate of 225,000 shares of Common Stock beneficially owned by former directors of Dragoneer. The business address for such selling securityholders is c/o Dragoneer Investment Group, LLC, One Letterman Drive, Building D, Suite M500, San Francisco, California, 94129. |
• | Vehicle parts proliferation: |
• | Internal technology systems: |
• | Growing connected car capabilities: |
• | TaaS and other new business models: |
• | ADAS and diagnostics systems: |
• | Vehicle Electrification and related infrastructure: 55-72 million by 2025 |
• | Multi-tenant cloud platform enabling flexibility and innovation: |
• | Deep domain expertise: |
• | Long-term customer relationships: |
• | Network access: |
• | Proven R&D engine: |
• | Proprietary data assets: |
• | Enterprise scale and support: |
• | Growing our customer base: |
• | Deepening relationships with existing customers: up-selling customers based on package and feature upgrades. We intend to build upon strong customer relationships and access to key customer decision makers to increase software adoption and usage. |
• | Expanding the breadth of our solutions: Estimating-IQ for repair, Enterprise Payments, and more. |
• | Broadening our network ecosystem: |
ecosystem through CCC. The breadth and depth of our platform creates network effects that accelerate the demand for our software solutions. We intend to extend our network of companies to enhance our value proposition and create new market growth opportunities. |
• | Growing our geographic footprint: |
• | Pursuing acquisitions: |
• | CCC Workflow: end-to-end two-way text communications. Our workflow solutions leverage a sophisticated rules engine to customize routing for escalations, review, and approval processes. Our network management capability powers insurance DRPs, enabling insurers to seamlessly connect and collaborate with repair facilities and other companies to provide accurate and timely information about a claim flow from the right party at the right time. |
• | CCC Estimating: best-in-class |
• | CCC Total Loss: |
• | CCC AI and Analytics: AI-enabled solutions. All of our core software offerings are supported by Analytics solutions that allow our customers to benchmark and manage their business performance across key performance indicators. |
• | CCC Casualty: |
• | CCC Estimating: Estimating-IQ upgrade incorporates AI into the repair estimating application to provide repairers with a jump start on estimating by applying machine learning to prepopulate estimates with parts and labor operations based on photos of vehicle damage and individual repair facility configurations. Our estimating solutions help reduce errors and improve cycle time for collision repairers and their partners. |
• | CCC Network Management: |
• | CCC Repair Workflow: Customer-to-shop |
• | CCC Repair Quality: |
• | CCC Parts Solutions: |
• | CCC Automotive Manufacturer Solutions: up-to-date |
• | CCC Lender Solutions: |
• | CCC Payments: |
• | Ease of implementation |
• | Flexibility |
applications via SDKs, deployed via HTML5, or enabled by API calls. In addition, customers can configure and adjust rules based on business outcomes, which can be deployed in real-time via the CCC cloud. For example, our configurable carrier workflow allows insurers to design custom workflows that create differentiated experiences and adjust parameters to deliver targeted results. |
• | Innovation |
• | Security and Quality |
• | Availability and Uptime |
• | Internally developed software in-house technology programs will be supported by large-scale consulting firms. |
• | P&C insurance software vendors |
• | Other ecosystem software vendors e-commerce platforms. |
Quarter Ending |
2022 |
2021 |
||||||||
Software NDR |
March 31 | 114 | % | 106 | % | |||||
June 30 | 110 | % | ||||||||
September 30 | 113 | % | ||||||||
December 31 | 115 | % |
Quarter Ending |
2022 |
2021 |
||||||||
Software GDR |
March 31 | 99 | % | 98 | % | |||||
June 30 | 98 | % | ||||||||
September 30 | 98 | % | ||||||||
December 31 | 98 | % |
• | Conversion and implementation of new customers |
• | Long-term customer relationships: end-markets we serve, and these relationships are a key component of our success given the long-term nature of our contracts and the interconnectedness of our network. We generate revenue through the sale of software subscriptions and our average contract is approximately three to five years in duration. As of March 31, 2022, our national carrier customers included 18 of the top 20 automotive insurers based on DWP, with average customer relationships spanning more than 10 years, and numerous exclusive arrangements. |
• | Expansion of solution adoption from existing customers: go-to-market |
• | Investment in R&D: |
• | Investment in Platform, Privacy, and Security: |
• | Investment in Sales and Marketing: |
business growth. Our sales and marketing expenses totaled $26.8 million and $19.4 million in the three months ended March 31, 2022 and 2021, respectively, $148.9 million, $74.7 million and $82.1 million, in the years ended December 31, 2021, 2020 and 2019, respectively. Our sales and marketing investments increased during the three months ended March 31, 2022 compared to the three months ended March 31, 2021, primarily due to a $6.5 million increase in personnel costs, including stock-based compensation, sales incentives and employee travel costs, a $0.3 million increase in marketing and event costs and a $0.3 million increase in consulting costs. |
(dollar amounts in thousands, except share and per share data) |
Three Months ended March 31 |
Change |
||||||||||||||
2022 |
2021 |
$ |
% |
|||||||||||||
Revenues |
$ | 186,823 | $ | 157,789 | $ | 29,034 | 18.4 | % | ||||||||
Cost of Revenues, exclusive of amortization of acquired technologies |
42,701 | 38,013 | 4,688 | 12.3 | % | |||||||||||
Amortization of acquired technologies |
6,695 | 6,580 | 115 | 1.7 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Cost of revenues (1) |
49,396 | 44,593 | 4,803 | 10.8 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Gross profit |
137,427 | 113,196 | 24,231 | 21.4 | % | |||||||||||
Operating expenses: |
||||||||||||||||
Research and development (1) |
35,681 | 30,624 | 5,057 | 16.5 | % | |||||||||||
Selling and marketing (1) |
26,802 | 19,417 | 7,385 | 38.0 | % | |||||||||||
General and administrative (1) |
44,207 | 37,839 | 6,368 | 16.8 | % | |||||||||||
Amortization of intangible assets |
18,080 | 18,077 | 3 | 0.0 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Total operating expenses |
124,770 | 105,957 | 18,813 | 17.8 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Operating income |
12,657 | 7,239 | 5,418 | 74.8 | % | |||||||||||
Other income (expense): |
60.9 | % | ||||||||||||||
Interest expense |
(7,341 | ) | (18,766 | ) | 11,425 | -100.0 | % | |||||||||
Gain on change in fair value of interest rate swaps |
— | 3,277 | (3,277 | ) | NM | |||||||||||
Change in fair value of warrant liabilities |
2,136 | — | 2,136 | NM | ||||||||||||
Gain on sale of cost method investment |
3,578 | — | 3,578 | -5.7 | % | |||||||||||
Other income, net |
82 | 87 | (5 | ) | ||||||||||||
|
|
|
|
|
|
|||||||||||
Total other income (expense) |
(1,545 | ) | (15,402 | 13,857 | 90.0 | % | ||||||||||
Income (loss) before income taxes |
11,112 | (8,163 | ) | 19,275 | NM | |||||||||||
Income tax benefit |
863 | 3,079 | (2,216 | ) | NM | |||||||||||
|
|
|
|
|
|
|||||||||||
Net income (loss) |
11,975 | (5,084 | ) | 17,059 | NM | |||||||||||
|
|
|
|
|
|
|||||||||||
Net income (loss) per share attributable to common stockholders: |
||||||||||||||||
Basic |
$ | 0.02 | $ | (0.01 | ) | |||||||||||
Diluted |
$ | 0.02 | $ | (0.01 | ) | |||||||||||
Weighted-average shares used in computing net income (loss) per share attributable to common stockholders: |
||||||||||||||||
Basic |
603,104,839 | 505,072,914 | ||||||||||||||
Diluted |
641,028,410 | 505,072,914 |
(1) | Includes stock-based compensation expense as follows (in thousands): |
Three Months Ended March 31, |
||||||||
2022 |
2021 |
|||||||
Cost of Revenue |
849 | 219 | ||||||
Research and development |
3,530 | 575 | ||||||
Sales and marketing |
4,830 | 555 | ||||||
General and administrative |
14,435 | 11,305 | ||||||
|
|
|
|
|||||
Total stock-based compensation |
23,644 | 12,654 | ||||||
|
|
|
|
Year Ended December 31, |
Change |
|||||||||||||||
(dollar amounts in thousands, except share and per share data) |
2021 |
2020 |
$ |
% |
||||||||||||
Revenue |
$ | 688,288 | $ | 633,063 | $ | 55,225 | 8.7 | % | ||||||||
Cost of revenue, exclusive of amortization of acquired technologies |
169,335 | 182,414 | (13,079 | ) | -7.2 | % | ||||||||||
Amortization of acquired technologies |
26,320 | 26,303 | 17 | 0.1 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Cost of revenue (1) |
195,655 | 208,717 | (13,062 | ) | -6.3 | % | ||||||||||
|
|
|
|
|
|
|||||||||||
Gross profit |
492,633 | 424,346 | 68,287 | 16.1 | % | |||||||||||
Operating expenses: |
||||||||||||||||
Research and development (1) |
165,991 | 109,508 | 56,483 | 51.6 | % | |||||||||||
Selling and marketing (1) |
148,861 | 74,710 | 74,151 | 99.3 | % | |||||||||||
General and administrative (1) |
250,098 | 90,838 | 159,260 | 175.3 | % | |||||||||||
Amortization of intangible assets |
72,358 | 72,310 | 48 | 0.1 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Total operating expenses |
637,308 | 347,366 | 289,942 | 83.5 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Operating (loss) income |
(144,675 | ) | 76,980 | (221,655 | ) | NM | ||||||||||
Other income (expense), net: |
||||||||||||||||
Interest expense |
(58,990 | ) | (77,003 | ) | 18,013 | 23.4 | % | |||||||||
Gain (loss) on change in fair value of interest rate swaps |
8,373 | (13,249 | ) | 21,622 | NM | |||||||||||
Change in fair value of warrant liabilities |
(64,501 | ) | — | (64,501 | ) | NM | ||||||||||
Loss on early extinguishment of debt |
(15,240 | ) | (8,615 | ) | (6,625 | ) | -76.9 | % | ||||||||
Other income, net |
114 | 332 | (218 | ) | -65.7 | % | ||||||||||
|
|
|
|
|
|
|||||||||||
Total other (expense) income, net |
(130,244 | ) | (98,535 | ) | (31,709 | ) | -32.2 | % | ||||||||
Pretax (loss), no income |
(274,919 | ) | (21,555 | ) | (253,364 | ) | -1175.4 | % | ||||||||
Income tax benefit |
26,000 | 4,679 | 21,321 | 455.7 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Net loss |
$ | (248,919 | ) | $ | (16,876 | ) | $ | (232,043 | ) | -1375.0 | % | |||||
|
|
|
|
|
|
|||||||||||
Net loss per share attributable to common stockholders—basic and diluted |
$ | (0.46 | ) | $ | (0.03 | ) | ||||||||||
Weighted-average shares used in computing net loss per share attributable to common stockholders—basic and diluted |
543,558,222 | 504,115,839 |
(1) | Includes stock-based compensation expense as follows (in thousands): |
Year Ended December 31, |
||||||||
2021 |
2020 |
|||||||
Cost of revenues |
$ | 13,644 | $ | 494 | ||||
Research and development |
40,681 | 1,174 | ||||||
Sales and marketing |
65,045 | 2,024 | ||||||
General and administrative |
142,625 | 7,644 | ||||||
|
|
|
|
|||||
Total stock-based compensation expense |
$ | 261,995 | $ | 11,336 | ||||
|
|
|
|
Year Ended December 31, |
Change |
|||||||||||||||
(dollar amounts in thousands, except share and per share data) |
2020 |
2019 |
$ |
% |
||||||||||||
Revenue |
$ | 633,063 | $ | 616,084 | $ | 16,979 | 2.8 | % | ||||||||
Cost of revenue, exclusive of amortization and impairment of acquired technologies (1) |
182,414 | 191,868 | (9,454 | ) | -4.9 | % | ||||||||||
Amortization of acquired technologies |
26,303 | 27,797 | (1,494 | ) | -5.4 | % | ||||||||||
Impairment of acquired technologies |
— | 5,984 | (5,984 | ) | NM | |||||||||||
|
|
|
|
|
|
|||||||||||
Cost of revenue |
208,717 | 225,649 | (16,932 | ) | -7.5 | % | ||||||||||
|
|
|
|
|
|
|||||||||||
Gross profit |
424,346 | 390,435 | 33,911 | 8.7 | % | |||||||||||
Operating expenses: |
||||||||||||||||
Research and development (1) |
109,508 | 114,005 | (4,497 | ) | -3.9 | % | ||||||||||
Selling and marketing (1) |
74,710 | 82,109 | (7,399 | ) | -9.0 | % | ||||||||||
General and administrative (1) |
90,838 | 78,128 | 12,710 | 16.3 | % | |||||||||||
Amortization of intangible assets |
72,310 | 81,329 | (9,019 | ) | -11.1 | % | ||||||||||
Impairment |
— | 201,066 | (201,066 | ) | NM | |||||||||||
|
|
|
|
|
|
|||||||||||
Total operating expenses |
347,366 | 556,637 | (209,271 | ) | -37.6 | % | ||||||||||
|
|
|
|
|
|
|||||||||||
Operating (loss) income |
76,980 | (166,202 | ) | 243,182 | NM | % | ||||||||||
Other income (expense), net: |
||||||||||||||||
Interest expense |
(77,003 | ) | (89,475 | ) | 12,472 | -13.9 | % | |||||||||
Loss on change in fair value of interest rate swaps |
(13,249 | ) | (22,432 | ) | 9,183 | -40.9 | % | |||||||||
Loss on early extinguishment of debt |
(8,615 | ) | — | (8,615 | ) | NM | ||||||||||
Other income, net |
332 | 476 | (144 | ) | -30.3 | % | ||||||||||
|
|
|
|
|
|
|||||||||||
Total other income (expense) |
(98,535 | ) | (111,431 | ) | 12,896 | -11.6 | % | |||||||||
Pretax Ioss |
(21,555 | ) | (277,633 | ) | 256,078 | -92.2 | % | |||||||||
Income tax benefit |
4,679 | 67,293 | (62,614 | ) | -93.0 | % | ||||||||||
|
|
|
|
|
|
|||||||||||
Net loss |
$ | (16,876 | ) | $ | (210,340 | ) | $ | 193,464 | -92.0 | % | ||||||
|
|
|
|
|
|
|||||||||||
Net loss per share attributable to common stockholders—basic and diluted |
$ | (0.03 | ) | $ | (0.42 | ) | ||||||||||
Weighted-average shares used in computing net loss per share attributable to common stockholders—basic and diluted |
504,115,839 | 503,453,127 |
(1) |
Includes stock-based compensation expense as follows (in thousands): |
Year Ended December 31, |
||||||||
2020 |
2019 |
|||||||
Cost of revenues |
$ | 494 | $ | 485 | ||||
Research and development |
1,174 | 1,216 | ||||||
Sales and marketing |
2,024 | 1,858 | ||||||
General and administrative |
7,644 | 3,565 | ||||||
|
|
|
|
|||||
Total stock-based compensation expense |
$ | 11,336 | $ | 7,124 | ||||
|
|
|
|
Three Months Ended March 31 |
Year ended December 31, |
|||||||||||||||||||
(amounts in thousands, except percentages) |
2022 |
2021 |
2021 |
2020 |
2019 |
|||||||||||||||
Gross Profit |
$ | 137,427 | $ | 113,196 | $ | 492,633 | $ | 424,346 | $ | 390,435 | ||||||||||
First Party Clinical Services—Gross Profit |
— | — | — | (3,429 | ) | (6,118 | ) | |||||||||||||
Amortization of acquired technologies |
6,695 | 6,580 | 26,320 | 26,303 | 27,797 | |||||||||||||||
Impairment of acquired technologies |
— | — | — | — | 5,984 | |||||||||||||||
Business combination transaction costs |
— | — | 905 | — | — | |||||||||||||||
Stock-based compensation |
$ | 933 | $ | 219 | 13,644 | 494 | 485 | |||||||||||||
Adjusted Gross Profit |
$ | 145,055 | $ | 119,995 | $ | 533,502 | $ | 447,714 | $ | 418,583 | ||||||||||
Gross Profit Margin |
74 | % | 72 | % | 72 | % | 67 | % | 63 | % | ||||||||||
Adjusted Gross Profit Margin |
78 | % | 76 | % | 78 | % | 75 | % | 73 | % |
(dollar amounts in thousands) |
Three Months Ended March 31, |
|||||||
2022 |
2021 |
|||||||
Net income (loss) |
$ | 11,975 | $ | (5,084 | ) | |||
Interest expense |
7,341 | 18,766 | ||||||
Income tax benefit |
(863 | ) | (3,079 | ) | ||||
Amortization of intangible assets |
18,080 | 18,077 | ||||||
Amortization of acquired technologies—Cost of revenue |
6,695 | 6,580 | ||||||
Depreciation and amortization related to software, equipment and property |
6,807 | 5,153 | ||||||
|
|
|
|
|||||
EBITDA |
50,035 | 40,413 | ||||||
Gain on change in fair value of interest rate swaps |
— | (3,277 | ) | |||||
Change in fair value of warrant liabilities |
(2,136 | ) | — | |||||
Stock-based compensation expense and related employer payroll tax |
24,656 | 12,654 | ||||||
Business combination transaction costs |
732 | 3,002 | ||||||
Lease abandonment |
1,222 | 909 | ||||||
Lease overlap costs |
1,338 | 924 | ||||||
Net costs related to divestiture |
60 | 772 | ||||||
M&A and integration costs |
1,407 | — | ||||||
Gain on sale of cost method investment |
(3,578 | ) | — | |||||
|
|
|
|
|||||
Adjusted EBITDA |
$ | 73,736 | $ | 55,397 | ||||
|
|
|
|
Year ended December 31, |
||||||||||||
(dollar amounts in thousands) |
2021 |
2020 |
2019 |
|||||||||
Net loss |
$ | (248,919 | ) | $ | (16,876 | ) | $ | (210,340 | ) | |||
Interest expense |
58,990 | 77,003 | 89,475 | |||||||||
Income tax benefit |
(26,000 | ) | (4,679 | ) | (67,293 | ) | ||||||
Amortization of intangible assets |
72,358 | 72,310 | 81,329 | |||||||||
Amortization of acquired technologies—Cost of revenue |
26,320 | 26,303 | 27,797 | |||||||||
Depreciation and amortization related to software, equipment and property |
24,451 | 17,749 | 18,391 | |||||||||
|
|
|
|
|
|
|||||||
EBITDA |
(92,800 | ) | 171,810 | (60,641 | ) | |||||||
(Gain) loss on change in fair value of interest rate swaps |
(8,373 | ) | 13,249 | 22,432 | ||||||||
Change in fair value of warrant liabilities |
64,501 | — | — | |||||||||
Impairment charge |
— | — | 207,050 | |||||||||
Stock-based compensation expense |
261,995 | 11,336 | 7,710 | |||||||||
Loss on early extinguishment of debt |
15,240 | 8,615 | — | |||||||||
Business combination transaction costs |
12,385 | 1,188 | — | |||||||||
Lease abandonment |
2,582 | — | — | |||||||||
Lease overlap costs |
3,697 | 35 | — | |||||||||
Net costs related to divestiture |
2,177 | (34,742 | ) | — | ||||||||
First Party Clinical Services—Revenue |
— | 31,313 | (46,042 | ) | ||||||||
First Party Clinical Services—Cost of revenue |
— | — | 39,924 | |||||||||
|
|
|
|
|
|
|||||||
Adjusted EBITDA |
$ | 261,404 | $ | 202,804 | $ | 170,433 | ||||||
|
|
|
|
|
|
(1) | a base rate determined by reference to the highest of (a) the rate last quoted by the Wall Street Journal as the “prime rate,” (b) the federal funds effective rate plus 0.50%, (c) one-month LIBOR plus 1.00% and (d) with respect to the Term B Loans, 1.50% and with respect to the Revolving Credit Facility, 1.00%, or |
(2) | a Eurocurrency rate determined by reference to LIBOR (other than with respect to Euros, Euribor and with respect to British Pounds Sterling, SONIA) with a term as selected by the Company, of one, three or six months (subject to (x) in the case of term loans, a 0.50% per annum floor and (y) in the case of revolving loans, a 0.00% per annum floor). |
(dollar amounts in thousands) |
Three Months Ended March 31, |
|||||||
2022 |
2021 |
|||||||
Net cash provided by operating activities |
$ | 48,865 | $ | 38,234 | ||||
Net cash used in investing activities |
(42,615 | ) | (4,686 | ) | ||||
Net cash provided by (used in) financing activities |
8,691 | (136,501 | ) | |||||
Net effect of exchange rate change |
12 | 9 | ||||||
|
|
|
|
|||||
Change in cash and cash equivalents |
12,953 | (102,944 | ) | |||||
|
|
|
|
Year ended December 31, |
||||||||||||
(dollar amounts in thousands) |
2021 |
2020 |
2019 |
|||||||||
Net cash provided by operating activities |
$ | 127,335 | $ | 103,943 | $ | 66,301 | ||||||
Net cash used in investing activities |
(48,598 | ) | (30,667 | ) | (21,055 | ) | ||||||
Net cash used in financing activities |
(58,440 | ) | (4,421 | ) | (9,428 | ) | ||||||
Net effect of exchange rate change |
129 | 62 | (70 | ) | ||||||||
|
|
|
|
|
|
|||||||
Change in cash and cash equivalents |
$ | 20,426 | $ | 68,917 | $ | 35,748 | ||||||
|
|
|
|
|
|
• | Revenue Recognition |
• | Valuation of Goodwill and Intangible Assets |
• | Stock-based Compensation |
• | Valuation of warrant liabilities |
• | Fair Value of Common Stock-Prior to the Business Combination, there was no public market for our common stock. For those periods included in our consolidated financial statements, fair values of the shares of common stock underlying our stock-based awards were estimated on each grant date by our board of directors. Our board of directors, with input from management considered, among other things, valuations of our common stock, which were prepared in accordance with the guidance provided by the American Institute of Certified Public Accountants 2013 Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation as well as the Advent Transaction for grants in 2017. |
• | Expected Term-The expected term represents the period that stock-based awards are expected to be outstanding and, for time-based awards, is determined using the simplified method that uses the weighted average of the time-to-vesting and the contractual life of the awards. |
• | Expected Volatility-As we have limited trading history for our common stock, the expected volatility was estimated based on the average volatility for comparable publicly traded companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, stage in the life cycle or area of specialty. |
• | Risk-Free Interest Rate-The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of awards. |
• | Expected Dividend Yield-Historically, we have not paid regular dividends on our common stock and have no plans to pay dividends on our common stock on a regular basis. We do not have a dividend policy. Therefore, we used an expected dividend yield of zero. |
• | Githesh Ramamurthy, President and Chief Executive Officer, Chairperson of the Board |
• | Brian Herb, Executive Vice President, Chief Financial and Administrative Officer |
• | Barrett Callaghan, Executive Vice President, Markets and Customer Success (1) |
(1) | Mr. Callaghan was promoted to this position on February 3, 2021, and previously served as CCC’s General Manager and Senior Vice President of Insurance Services. On April 29, 2022, CCC announced that Mr. Callaghan would transition from his role as CCC’s Executive Vice President, Markets and Customer Success to a senior advisory role with CCC, effective May 31, 2022, and be retained as a part-time employee by CCC. In this role, it is anticipated that Mr. Callaghan will, among other things, be involved in market related activities, provide strategic insights and support the development of key personnel. |
Name and Principal Position |
Year |
Salary 1 ($) |
Bonus 2 ($) |
Stock Awards 3 ($) |
Option Awards 4 ($) |
Non-Equity Incentive Plan Compensation 5 ($) |
All Other Compensation 6 ($) |
Total ($) |
||||||||||||||||||||||||
Githesh Ramamurthy |
2021 | 806,140 | 675,000 | 131,860,500 | 1,622,396 | 746,800 | 1,394,239 | 137,105,076 | ||||||||||||||||||||||||
Chief Executive Officer |
2020 | 782,661 | — | 704,590 | 16,023 | 1,503,274 | ||||||||||||||||||||||||||
Brian Herb |
2021 | 562,693 | 600,000 | 3,423,750 | 260,636 | 10,138 | 4,857,217 | |||||||||||||||||||||||||
Executive Vice President, Chief Financial and Administrative Officer | 2020 | 473,846 | 300,000 | 1,560,000 | 1,494,480 | 247,500 | 21,105 | 4,096,931 | ||||||||||||||||||||||||
Barrett Callaghan |
2021 | 415,112 | 3,138,438 | 192,499 | 560,010 | 4,306,058 | ||||||||||||||||||||||||||
Executive Vice President, Markets and Customer Success | 2020 | 377,478 | — | 459,840 | 212,390 | 16,845 | 1,066,553 | |||||||||||||||||||||||||
(1) | Amounts in this column represent the annual base salary earned by each NEO. On March 21, 2021, Mr. Ramamurthy and Mr. Herb each received a merit base salary increase of 3%, and Mr. Callaghan received a base salary increase of 12% in connection with his promotion to Executive Vice President, Markets and Customer Success. |
(2) | Mr. Ramamurthy and Mr. Herb each received a transaction bonus in connection with the consummation of the business combination, in the amount of $675,000 and $600,000, respectively. |
(3) | Amounts in this column represent the aggregate grant date fair value of stock awards granted to the NEOs in 2021, computed in accordance with FASB ASC Topic 718. The grant date fair value for awards of time-based restricted stock units (“RSUs”) and awards of performance-based restricted stock units (“PSUs”) that vest based on the achievement of CCC’s compound annual revenue growth rate percentage and minimum EBITDA margin targets during a specified performance period is calculated using the closing market price of our common stock on the grant date. The grant date fair value for awards of PSUs that vest based on the achievement of CCC’s total shareholder return during a specified performance period is estimated based on the use of a Monte Carlo valuation methodology and the probable outcome of the achievement of the performance conditions, as determined in accordance with FASB Topic 718. For additional information on the valuation assumptions for these awards, see Note 20 (Stock Incentive Plans) to CCC’s condensed consolidated financial statements included elsewhere in this prospectus for additional information. The maximum grant date fair value of the PSUs granted to the NEOs, based on the original grant date fair value, is $143,928,000 for Mr. Ramamurthy, $3,364,500 for Mr. Herb, and $3,084,125 for Mr. Callaghan. For Mr. Ramamurthy, the amount in this column also includes the value of an award of unrestricted shares, with a grant date fair value of $8,044,500, granted to Mr. Ramamurthy in 2021. |
(4) | Amounts in this column represent the aggregate grant date fair value for option awards granted to the NEOs, computed in accordance with FASB ASC Topic 718. A discussion of the methodology for determining grant date fair value may be found in Note 20 (Stock Incentive Plans) to our condensed consolidated financial statements included elsewhere in this prospectus. |
(5) | Amounts in this column represent performance-based annual cash bonuses earned in 2020 and 2021 by each of the NEOs pursuant to CCC’s annual incentive plan. |
(6) | The amounts in this column are comprised of the following: |
All Other Compensation Table |
Year |
Individual Supplemental Disability Premiums |
401(K) Match |
One-time Payment (a) |
Health Club Reimbursement |
Health Club Gross Up |
Headquarters Parking Reimbursement |
Headquarters Parking Gross Up |
Total |
|||||||||||||||||||||||||||
Githesh Ramamurthy |
2021 | 5,100 | 8,700 | 1,377,492 | 199 | 129 | 1,560 | 1,059 | 1,394,239 | |||||||||||||||||||||||||||
Chief Executive Officer |
||||||||||||||||||||||||||||||||||||
Brian Herb |
2021 | 887 | 8,700 | — | — | 390 | 162 | 10,138 | ||||||||||||||||||||||||||||
Executive Vice President, Chief Financial and Administrative Officer |
||||||||||||||||||||||||||||||||||||
Barrett Callaghan |
2021 | 4,396 | 8,700 | 544,105 | 1,596 | 661 | 390 | 162 | 560,010 | |||||||||||||||||||||||||||
Executive Vice President, Markets and Customer Success |
(a) | In connection with special dividends paid in March 2021 and August 2021 to stockholders of Cypress Holdings Inc. (“Cypress Holdings”), certain option holders received a one-time cash payment to compensate for the reduction in the fair value of the underlying shares without a corresponding decrease in the exercise price, which one-time cash payment was paid substantially concurrently with the closing of the business combination. In accordance with the foregoing, Mr. Ramamurthy and Mr. Callaghan received the following cash payments, respectively: $1,377,492 and $544,105. |
Option Awards (1) |
Stock Awards |
|||||||||||||||||||||||||||||||||||||||
Grant Date |
Number of Securities Underlying Unexercised Options |
Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) |
Option Exercise Price ($) |
Option Expiration Date |
Number of Share or Units of Stock That Have Not Vested (#) |
Market Value of Shares or Units of Stock That Have Not Vested ($) (2) |
Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights that have Not Vested (#) |
Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights that have Not Vested ($) (2) |
||||||||||||||||||||||||||||||||
Name |
Exercisable (#) |
Unexercisable (#) |
||||||||||||||||||||||||||||||||||||||
Githesh Ramamurthy |
7/10/2017 | (3) |
7,492,115 | 1,873,028 | $ | 2.50 | 7/10/2027 | |||||||||||||||||||||||||||||||||
Chief Executive Officer | 7/10/2017 | (4) |
9,365,143 | $ | 2.50 | 7/10/2027 | ||||||||||||||||||||||||||||||||||
1/13/2021 | (5) |
442,034 | $ | 8.58 | 1/13/2031 | |||||||||||||||||||||||||||||||||||
10/21/2021 | (6) |
2,400,000 | $ | 27,336,000 | ||||||||||||||||||||||||||||||||||||
10/21/2021 | (7) |
4,800,000 | $ | 54,672,000 | ||||||||||||||||||||||||||||||||||||
10/21/2021 | (8) |
1,200,000 | $ | 13,668,000 | ||||||||||||||||||||||||||||||||||||
Brian Herb |
4/1/2020 | (3) |
110,679 | 442,715 | $ | 4.05 | 4/1/2030 | |||||||||||||||||||||||||||||||||
Executive Vice President, Chief Financial and Administrative |
4/1/2020 | (4) |
553,394 | $ | 4.05 | 4/1/2030 | ||||||||||||||||||||||||||||||||||
10/21/2021 | (6) |
150,000 | $ | 1,708,500 | ||||||||||||||||||||||||||||||||||||
10/21/2021 | (7) |
75,000 | $ | 854,250 | ||||||||||||||||||||||||||||||||||||
10/21/2021 | (8) |
37,500 | $ | 427,125 | ||||||||||||||||||||||||||||||||||||
Barrett Callaghan Executive Vice President, Markets and Customer Success |
7/10/2017 | (3) |
681,101 | 170,275 | $ | 2.50 | 7/10/2027 | |||||||||||||||||||||||||||||||||
7/10/2017 | (4) |
851,376 | $ | 2.50 | 7/10/2027 | |||||||||||||||||||||||||||||||||||
4/1/2020 | (3) |
34,055 | 136,220 | $ | 4.05 | 4/1/2030 | ||||||||||||||||||||||||||||||||||
4/1/2020 | (4) |
170,275 | $ | 4.05 | 4/1/2030 | |||||||||||||||||||||||||||||||||||
10/21/2021 | (6) |
137,500 | $ | 1,566,125 | ||||||||||||||||||||||||||||||||||||
10/21/2021 | (7) |
68,750 | $ | 783,063 | ||||||||||||||||||||||||||||||||||||
10/21/2021 | (8) |
34,375 | $ | 391,531 |
(1) | In connection with the business combination, each option granted under the 2017 Option Plan to purchase shares of Cypress Holdings stock was assumed by CCC and converted into an option under CCC’s 2021 Incentive Equity Plan (the “2021 Plan”) to purchase a specified number of shares of CCC’s common stock, based on the exchange ratio of 1:340.5507, rounded down to the nearest whole number of shares. For more information on this conversion of equity awards, see Note 3 to our CCC’s condensed consolidated financial statements included elsewhere in this prospectus for additional information for the year-ended December 31, 2021 . |
(2) | Amounts in this column were calculated using CCC’s closing stock price of $11.39 as of December 31, 2021. |
(3) | Represents grants of time-based stock options, each of which vest 20% on each of the first five anniversaries of the applicable vesting commencement date which, for options granted on July 10, 2017 is April 27, 2017 and for options granted on April 1, 2020 is April 1, 2020, in each case, subject to continued employment through the applicable vesting date. |
(4) | Represents awards of performance-based stock options granted under the 2017 Option Plan, 100% of which were deemed to vest in connection with the consummation of the business combination and are fully vested. |
(5) | Represents an award of performance-based stock options granted under the 2017 Option Plan, 100% of which was deemed to vest in connection with the consummation of the business combination and is fully vested. |
(6) | Represents awards of RSUs granted under the 2021 Plan, each of which vest 25% on each of the first four anniversaries of July 30, 2021, subject to continued employment through the applicable vesting date. |
(7) | Represents awards of PSUs under the 2021 Plan, which vest based on the achievement of CCC’s compound annual revenue growth rate percentage (“Revenue CAGR”) and minimum EBITDA margin targets during the period beginning on January 1, 2021 and ending on December 31, 2023, subject to continued employment through the date the Board certifies the achievement of the performance conditions. For Mr. Ramamurthy, 25% of the target number of PSUs will vest at minimum achievement, 100% will vest at target achievement, and 150% will vest at maximum achievement. For Messrs. Herb and Callaghan, 50% of the target number of PSUs will vest at minimum achievement, 100% will vest at target achievement, and 200% will vest at maximum achievement. Amounts shown above reflect the number of PSUs that would vest if the target level of performance is achieved. |
(8) | Represents awards of PSUs under the 2021 Plan, which vest based on the achievement of CCC’s total shareholder return (“TSR”) during the period beginning on August 2, 2021 and ending on December 31, 2023, subject to continued employment through the date the Board certifies the achievement of the performance conditions. For Mr. Ramamurthy, 25% of the target number of PSUs will vest at minimum achievement, 100% will vest at target achievement, and 150% will vest at maximum achievement. For Messrs. Herb and Callaghan, 50% |
of the target number of PSUs will vest at minimum achievement, 100% will vest at target achievement, and 200% will vest at maximum achievement. Amounts shown above reflect the number of PSUs that would be earned if the threshold level of performance is achieved. |
• | Mr. Ramamurthy received 92.6% of his target cash incentive (92.6% company performance and 100% individual performance multiplier). |
• | Mr. Herb received 92.6% of his target cash incentive (92.6% company performance and 100% individual performance multiplier). |
• | Mr. Callaghan received 92.6% of his target cash incentive (92.6% company performance and 100% individual performance multiplier). |
Named Executive Officer |
TSR PSUs 1 |
Revenue CAGR PSUs 2 |
RSUs 3 |
|||||||||
Githesh Ramamurthy |
4,800,000 | 4,800,000 | 2,400,000 | |||||||||
Brian Herb |
75,000 | 75,000 | 150,000 | |||||||||
Barrett Callaghan |
68,750 | 68,750 | 137,500 |
(1) | Earned based on CCC’s TSR during the period from August 2, 2021 through Dec. 31, 2023. For Mr. Ramamurthy, 25% of the target number of TSR PSUs will vest at minimum achievement and 150% will |
vest at maximum achievement. For Messrs. Herb and Callaghan, 50% of the target number of TSR PSUs will vest at minimum achievement and 200% will vest at maximum achievement. |
(2) | Earned based on CCC’s Revenue CAGR and a minimum EBITDA margin target during the period from January 1, 2021 through Dec. 31, 2023. For Mr. Ramamurthy, 25% of the target number of Revenue CAGR PSUs will vest at minimum achievement and 150% will vest at maximum achievement. For Messrs. Herb and Callaghan, 50% of the target number of Revenue CAGR PSUs will vest at minimum achievement and 200% will vest at maximum achievement. |
(3) | Vest 25% on each of the first four anniversaries of July 30, 2021, subject to continued employment through the applicable vesting date. |
• | Mr. Ramamurthy will not be eligible to receive any additional incentive equity grants from CCC until July 30, 2025; |
• | Following July 30, 2025, Mr. Ramamurthy will be eligible to receive an incentive equity grant only if CCC’s stock price is equal to or greater than $25 per share on the applicable date of grant; and |
• | Beginning in 2022, Mr. Ramamurthy will no longer be eligible to participate in CCC’s annual incentive plan (or any other similar plan, program or policy) during his employment or service with CCC, and any cash compensation received by Mr. Ramamurthy will be limited solely to base salary. |
Name |
Fees Earned or Paid in Cash ($) 1 |
Option Awards ($) 2 |
Stock Awards ($) 3 |
Total ($) |
||||||||||||
Eileen Schloss |
60,000 | 319,275 | 379,275 | |||||||||||||
Bill Ingram |
60,000 | 624,958 | 319,275 | 1,004,233 | ||||||||||||
Teri Williams |
58,333 | 624,958 | 290,250 | 973,541 |
(1) | Represents the $15,000 quarterly retainer paid to each of our eligible non-employee directors during fiscal year 2021 for their service on the Board. Ms. Williams’ payments were prorated based on the commencement of her directorship in January 2021. |
(2) | Represents the aggregate grant date fair value of options granted to Mr. Ingram and Ms. Williams in January 2021 under the 2017 Option Plan (which were converted to options under the 2021 Plan as described below), computed in accordance with FASB ASC Topic 718. The options vest 20% on the first five anniversaries of January 13, 2021, subject to continued service through the applicable vesting date. In connection with the business combination, each option granted under the 2017 Option Plan to purchase shares of Cypress Holdings stock was assumed by CCC and converted into an option under the 2021 Plan to purchase a specified number of shares of CCC’s common stock, based on the exchange ratio of 1:340.5507, rounded down to the nearest whole number of shares. For more information on this conversion of equity awards, see Note 3 to CCC’s condensed consolidated financial statements included elsewhere in this prospectus for additional information . |
(3) | Represents the aggregate grant date fair value of the RSUs granted to certain of our non-employee directors in October 2021, computed in accordance with FASB ASC Topic 718. See Note 20 to CCC’s condensed consolidated financial statements included elsewhere in this prospectus for additional information for a discussion of all assumptions made by us in determining the grant date fair value of the RSUs. The aggregate number of outstanding RSUs held by each non-employee director in the table above as of December 31, 2021 were, for Ms. Schloss: 27,500, Mr. Ingram: 27,500, and Ms. Williams: 25,000, and in each case such RSUs will become fully vested on July 30, 2022, subject to continued service through such vesting date. |
Name |
Age |
Position | ||||
Githesh Ramamurthy |
61 | Chief Executive Officer and Chairman | ||||
Brian Herb |
49 | Executive Vice President, Chief Financial and Administrative Officer | ||||
Mary Jo Prigge |
64 | Executive Vice President, Chief Service Delivery Officer | ||||
John Goodson |
57 | Executive Vice President, Chief Technology Officer | ||||
Marc Fredman |
44 | Senior Vice President, Chief Strategy Officer | ||||
Shivani Govil |
51 | Senior Vice President, Chief Product Officer | ||||
Steven G. Puccinelli |
63 | Director | ||||
William Ingram |
65 | Director | ||||
Eileen Schloss |
69 | Director | ||||
Teri Williams |
64 | Director | ||||
Christopher Egan |
45 | Director | ||||
Eric Wei |
46 | Director | ||||
Lauren Young |
39 | Director |
• | assisting board oversight of (1) the integrity of our financial statements, (2) our compliance with legal and regulatory requirements, (3) our independent registered public accounting firm’s qualifications and independence, and (4) the performance of our internal audit function and independent auditors; the appointment, compensation, retention, replacement, and oversight of the work of the independent auditors and any other independent registered public accounting firm engaged by us; |
• | pre-approving all audit and non-audit services to be provided by the independent auditors or any other registered public accounting firm engaged by us, and establishing pre-approval policies and procedures; reviewing and discussing with the independent auditors all relationships the auditors have with us in order to evaluate their continued independence; |
• | setting clear policies for audit partner rotation in compliance with applicable laws and regulations; obtaining and reviewing a report, at least annually, from the independent registered public accounting firm describing (1) the independent auditor’s internal quality-control procedures and (2) any material issues raised by the most recent internal quality-control review, or peer review, of the audit firm, or by any inquiry or investigation by governmental or professional authorities, within the preceding five years respecting one or more independent audits carried out by the firm and any steps taken to deal with such issues; |
• | meeting to review and discuss our annual audited financial statements and quarterly financial statements with management and the independent auditor, including reviewing our specific disclosures under “Management’s Discussion and Analysis of Financial Condition and Results of Operations”; reviewing and approving any related party transaction required to be disclosed pursuant to Item 404 of Regulation S-K promulgated by the SEC prior to us entering into such transaction; and |
• | reviewing with management, the independent auditors, and our legal advisors, as appropriate, any legal, regulatory or compliance matters, including any correspondence with regulators or government agencies and any employee complaints or published reports that raise material issues regarding our financial statements or accounting policies and any significant changes in accounting standards or rules promulgated by the Financial Accounting Standards Board, the SEC or other regulatory authorities. |
• | reviewing and approving on an annual basis the corporate goals and objectives relevant to our chief executive officer’s compensation, evaluating our chief executive officer’s performance in light of such goals and objectives and determining and approving the remuneration (if any) of our chief executive officer’s based on such evaluation; |
• | reviewing and making recommendations to the Board with respect to the compensation, and any incentive compensation and equity based plans that are subject to board approval of all of our other officers; |
• | reviewing our executive compensation policies and plans; |
• | implementing and administering our incentive compensation equity-based remuneration plans; |
• | assisting management in complying with our proxy statement and annual report disclosure requirements; |
• | approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our officers and employees; |
• | producing a report on executive compensation to be included in our annual proxy statement; and |
• | reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors. |
• | identifying, screening and reviewing individuals qualified to serve as directors, consistent with criteria approved by the board, and recommending to the board of directors candidates for nomination for appointment at the annual general meeting or to fill vacancies on the board of directors; |
• | developing and recommending to the board of directors and overseeing implementation of our corporate governance guidelines; |
• | coordinating and overseeing the annual self-evaluation of the board of directors, its committees, individual directors and management in the governance of the company; and |
• | reviewing on a regular basis our overall corporate governance and recommending improvements as and when necessary. |
• | attract, retain and motivate senior management leaders who are capable of advancing CCC’s mission and strategy and, ultimately, creating and maintaining its long-term equity value; |
• | seek to pay competitive cash compensation at the market median of our peer group and in the first quartile for total compensation including long term compensation; |
• | reward senior management in a manner aligned with CCC’s financial performance; and |
• | align senior management’s interests with CCC’s equity owners’ long-term interests through equity participation and ownership. |
• | 1% of the total number of shares of our Common Stock then outstanding; or |
• | the average weekly reported trading volume of our Common Stock during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale. |
• | the issuer of the securities that was formerly a shell company has ceased to be a shell company; |
• | the issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act; |
• | the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding twelve months (or such shorter period that the issuer was required to file such reports and materials), other than Form 8-K reports; and |
• | at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting its status as an entity that is not a shell company. |
• | an individual who is a citizen or resident of the United States; |
• | a corporation (or any other entity treated as a corporation for United States federal income tax purposes) that is created or organized in or under the laws of the United States, any state thereof or the District of Columbia; |
• | an estate the income of which is subject to United States federal income taxation regardless of its source; or |
• | a trust if it (i) is subject to the primary supervision of a court within the United States and one or more United States persons have the authority to control all substantial decisions of the trust or (ii) has a valid election in effect under applicable United States Treasury regulations to be treated as a United States person. |
• | the gain is effectively connected with a trade or business of the non-U.S. holder in the United States (and, if required by an applicable income tax treaty, is attributable to a United States permanent establishment of the non-U.S. holder); |
• | the non-U.S. holder is an individual who is present in the United States for 183 days or more in the taxable year of that disposition, and certain other conditions are met; or |
• | we are or have been a “United States real property holding corporation” for United States federal income tax purposes and certain other conditions are met. |
• | purchases by a broker-dealer as principal and resale by such broker-dealer for its own account pursuant to this prospectus; |
• | ordinary brokerage transactions and transactions in which the broker solicits purchasers; |
• | block trades in which the broker-dealer so engaged will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction; |
• | an over-the-counter |
• | through trading plans entered into by a Selling Holder pursuant to Rule 10b5-1 under the Exchange Act that are in place at the time of an offering pursuant to this prospectus and any applicable prospectus supplement hereto that provide for periodic sales of their securities on the basis of parameters described in such trading plans; |
• | through one or more underwritten offerings on a firm commitment or best efforts basis; |
• | settlement of short sales entered into after the date of this prospectus; |
• | agreements with broker-dealers to sell a specified number of the securities at a stipulated price per share or warrant; |
• | distribution to employees, members, limited partners or stockholders of the Selling Holders; |
• | by pledge to secured debts and other obligations; |
• | delayed delivery arrangements; |
• | in “at the market” offerings, as defined in Rule 415 under the Securities Act, at negotiated prices, at prices prevailing at the time of sale or at prices related to such prevailing market prices, including sales made directly on a national securities exchange or sales made through a market maker other than on an exchange or other similar offerings through sales agents; |
• | directly to purchasers, including through a specific bidding, auction or other process or in privately negotiated transactions; |
• | through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; |
• | through a combination of any of the above methods of sale; or |
• | any other method permitted pursuant to applicable law. |
• | the specific securities to be offered and sold; |
• | the names of the Selling Holders; |
• | the respective purchase prices and public offering prices, the proceeds to be received from the sale, if any, and other material terms of the offering; |
• | settlement of short sales entered into after the date of this prospectus; |
• | the names of any participating agents, broker-dealers or underwriters; and |
• | any applicable commissions, discounts, concessions and other items constituting compensation from the Selling Holders. |
Audited Consolidated Financial Statements |
||||
F-2 | ||||
F-3 | ||||
F-4 | ||||
F-5 | ||||
F-7 | ||||
F-8 | ||||
Unaudited Interim Condensed Consolidated Financial Statements (Unaudited) |
||||
F-47 | ||||
F-48 | ||||
F-49 | ||||
F-51 | ||||
F-52 |
December 31, |
December 31, |
|||||||
2021 |
2020 |
|||||||
ASSETS |
||||||||
CURRENT ASSETS: |
||||||||
Cash and cash equivalents |
$ |
$ |
||||||
Accounts receivable—Net of allowances of $ |
||||||||
Income taxes receivable |
||||||||
Deferred contract costs |
||||||||
Other current assets |
||||||||
|
|
|
|
|||||
Total current assets |
||||||||
|
|
|
|
|||||
SOFTWARE, EQUIPMENT, AND PROPERTY—Net |
||||||||
OPERATING LEASE ASSETS |
— |
|||||||
INTANGIBLE ASSETS—Net |
||||||||
GOODWILL |
||||||||
DEFERRED FINANCING FEES, REVOLVER—Net |
||||||||
DEFERRED CONTRACT COSTS |
||||||||
EQUITY METHOD INVESTMENT |
— |
|||||||
OTHER ASSETS |
||||||||
|
|
|
|
|||||
TOTAL |
$ |
$ |
||||||
|
|
|
|
|||||
LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY |
||||||||
CURRENT LIABILITIES: |
||||||||
Accounts payable |
$ |
$ |
||||||
Accrued expenses |
||||||||
Income taxes payable |
||||||||
Current portion of long-term debt |
||||||||
Current portion of long-term licensing agreement—Net |
||||||||
Operating lease liabilities |
— |
|||||||
Deferred revenues |
||||||||
|
|
|
|
|||||
Total current liabilities |
||||||||
|
|
|
|
|||||
LONG-TERM DEBT: |
||||||||
First Lien Term Loan—Net |
— |
|||||||
Term B Loan—Net |
— |
|||||||
|
|
|
|
|||||
Total long-term debt |
||||||||
|
|
|
|
|||||
DEFERRED INCOME TAXES—Net |
||||||||
LONG-TERM LICENSING AGREEMENT—Net |
||||||||
OPERATING LEASE LIABILITIES |
— |
|||||||
WARRANT LIABILITIES |
— |
|||||||
OTHER LIABILITIES |
||||||||
|
|
|
|
|||||
Total liabilities |
||||||||
|
|
|
|
|||||
COMMITMENTS AND CONTINGENCIES (Notes 22 and 23) |
||||||||
MEZZANINE EQUITY: |
||||||||
Redeemable non-controlling interest |
||||||||
STOCKHOLDERS’ EQUITY: |
||||||||
Preferred stock, $ |
||||||||
Common stock—$ |
||||||||
Additional paid-in capital |
||||||||
Accumulated deficit |
( |
) |
( |
) | ||||
Accumulated other comprehensive loss |
( |
) |
( |
) | ||||
|
|
|
|
|||||
Total stockholders’ equity |
||||||||
|
|
|
|
|||||
TOTAL |
$ |
$ |
||||||
|
|
|
|
2021 |
2020 |
2019 |
||||||||||
REVENUES |
$ |
$ |
$ |
|||||||||
COST OF REVENUES |
||||||||||||
Cost of revenues, exclusive of amortization and impairment of acquired technologies |
||||||||||||
Amortization of acquired technologies |
||||||||||||
Impairment of acquired technologies |
||||||||||||
Total cost of revenues |
||||||||||||
GROSS PROFIT |
||||||||||||
OPERATING EXPENSES: |
||||||||||||
Research and development |
||||||||||||
Selling and marketing |
||||||||||||
General and administrative |
||||||||||||
Amortization of intangible assets |
||||||||||||
Impairment of goodwill |
||||||||||||
Impairment of intangible assets |
||||||||||||
Total operating expenses |
||||||||||||
OPERATING (LOSS) INCOME |
( |
) |
( |
) | ||||||||
INTEREST EXPENSE |
( |
) |
( |
) |
( |
) | ||||||
GAIN (LOSS) ON CHANGE IN FAIR VALUE OF INTEREST RATE SWAPS |
( |
) |
( |
) | ||||||||
CHANGE IN FAIR VALUE OF WARRANT LIABILITIES |
( |
) |
— |
— |
||||||||
LOSS ON EARLY EXTINGUISHMENT OF DEBT |
( |
) |
( |
) |
||||||||
OTHER INCOME — Net |
||||||||||||
PRETAX LOSS |
( |
) |
( |
) |
( |
) | ||||||
INCOME TAX BENEFIT |
||||||||||||
NET LOSS INCLUDING NON-CONTROLLING INTEREST |
( |
) |
( |
) |
( |
) | ||||||
Less: net loss attributable to non-controlling interest |
||||||||||||
NET LOSS ATTRIBUTABLE TO CCC INTELLIGENT SOLUTIONS HOLDINGS INC. |
$ |
( |
) |
$ |
( |
) |
$ |
( |
) | |||
Net loss per share attributable to common stockholders—basic and diluted |
$ |
( |
) |
$ |
( |
) |
$ |
( |
) | |||
Weighted-average shares used in computing net loss per share attributable to common stockholders—basic and diluted |
||||||||||||
COMPREHENSIVE LOSS: |
||||||||||||
Net loss including non-controlling interest |
( |
) |
( |
) |
( |
) | ||||||
Other comprehensive (loss) income—Foreign currency translation adjustment |
( |
) |
( |
) | ||||||||
COMPREHENSIVE LOSS INCLUDING NON-CONTROLLING INTEREST |
( |
) |
( |
) |
( |
) | ||||||
Less: comprehensive loss attributable to non-controlling interest |
||||||||||||
COMPREHENSIVE LOSS ATTRIBUTABLE TO CCC INTELLIGENT |
||||||||||||
SOLUTIONS HOLDINGS INC. |
$ | ( |
) | $ | ( |
) | $ | ( |
) | |||
Redeemable Non-Controlling |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issued Preferred Stock |
CCCIS Issued Common Stock |
Additional Paid-In |
Retained Earnings (Accumulated |
Accumulated Other Comprehensive |
Total Stockholders’ |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Interest |
Series A |
Series B |
Common Stock |
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of |
Par |
Number of |
Par |
Number of |
Par |
Number of |
Par |
|||||||||||||||||||||||||||||||||||||||||||||||||
Shares |
Value |
Shares |
Value |
Shares |
Value |
Shares |
Value |
Capital |
Deficit) |
Loss |
Equity |
|||||||||||||||||||||||||||||||||||||||||||||
BALANCE—December 31, 2018 (as previously reported) |
— |
$ |
— |
$ |
$ |
— |
— |
$ |
— |
$ |
$ |
$ |
( |
) |
$ |
|||||||||||||||||||||||||||||||||||||||||
Retrospective application of the recapitalization due to |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Combination (Note 3) |
— |
— |
— |
( |
) |
( |
) |
( |
) |
— |
( |
) |
— |
— |
— |
|||||||||||||||||||||||||||||||||||||||||
BALANCE—December 31, 2018, effect of Business |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Combination |
— |
— |
— |
— |
— |
— |
— |
( |
) |
|||||||||||||||||||||||||||||||||||||||||||||||
Cumulative effect of change in accounting principle related to revenue recognition |
— |
— |
— |
— |
— |
— |
— |
— |
— |
— |
— |
|||||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation expense |
— |
— |
— |
— |
— |
— |
— |
— |
— |
— |
— |
|||||||||||||||||||||||||||||||||||||||||||||
Exercise of stock options—net of tax |
— |
— |
— |
— |
— |
— |
— |
— |
— |
— |
||||||||||||||||||||||||||||||||||||||||||||||
Repurchase and cancellation of common stock |
— |
— |
— |
— |
— |
— |
— |
( |
) |
— |
( |
) |
— |
— |
( |
) | ||||||||||||||||||||||||||||||||||||||||
Exchange of Series A common stock for Series B common stock |
— |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Foreign currency translation adjustment |
— |
— |
— |
— |
— |
— |
— |
— |
— |
— |
— |
( |
) |
( |
) | |||||||||||||||||||||||||||||||||||||||||
Net loss |
— |
— |
— |
— |
— |
— |
— |
— |
— |
— |
( |
) |
— |
( |
) | |||||||||||||||||||||||||||||||||||||||||
BALANCE—December 31, 2019 |
— |
— |
— |
— |
— |
— |
— |
( |
) |
( |
) |
|||||||||||||||||||||||||||||||||||||||||||||
Issuance of non-controlling interest in subsidiary |
— |
— |
— |
— |
— |
— |
— |
— |
— |
— |
— |
— |
||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock |
— |
— |
— |
— |
— |
— |
— |
— |
— |
— |
||||||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation expense |
— |
— |
— |
— |
— |
— |
— |
— |
— |
— |
— |
|||||||||||||||||||||||||||||||||||||||||||||
Exercise of stock options—net of tax |
— |
— |
— |
— |
— |
— |
— |
— |
— |
— |
||||||||||||||||||||||||||||||||||||||||||||||
Repurchase and cancellation of common stock |
— |
— |
— |
— |
— |
— |
— |
( |
) |
— |
( |
) |
— |
— |
( |
) | ||||||||||||||||||||||||||||||||||||||||
Foreign currency translation adjustment |
— |
— |
— |
— |
— |
— |
— |
— |
— |
— |
— |
|||||||||||||||||||||||||||||||||||||||||||||
Net loss |
— |
— |
— |
— |
— |
— |
— |
— |
— |
— |
( |
) |
— |
( |
) | |||||||||||||||||||||||||||||||||||||||||
Redeemable Non-Controlling |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issued Preferred Stock |
CCCIS Issued Common Stock |
Additional Paid-In |
Retained Earnings (Accumulated |
Accumulated Other Comprehensive |
Total Stockholders’ |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Interest |
Series A |
Series B |
Common Stock |
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of |
Par |
Number of |
Par |
Number of |
Par |
Number of |
Par |
|||||||||||||||||||||||||||||||||||||||||||||||||
Shares |
Value |
Shares |
Value |
Shares |
Value |
Shares |
Value |
Capital |
Deficit) |
Loss |
Equity |
|||||||||||||||||||||||||||||||||||||||||||||
BALANCE—December 31, 2020 |
— |
— |
— |
— |
— |
— |
( |
) |
( |
) |
||||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock |
— |
— |
— |
— |
— |
— |
— |
— |
— |
— |
||||||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation expense |
— |
— |
— |
— |
— |
— |
— |
— |
— |
— |
||||||||||||||||||||||||||||||||||||||||||||||
Net equity infusion from the Business Combination |
— |
— |
— |
— |
— |
— |
— |
— |
— |
|||||||||||||||||||||||||||||||||||||||||||||||
Exercise of stock options—net of tax |
— |
— |
— |
— |
— |
— |
— |
— |
— |
— |
||||||||||||||||||||||||||||||||||||||||||||||
Exercise of Warrants—Net |
— |
— |
— |
— |
— |
— |
— |
— |
— |
|||||||||||||||||||||||||||||||||||||||||||||||
Dividends to CCCIS stockholders |
— |
— |
— |
— |
— |
— |
— |
— |
— |
— |
( |
) |
— |
( |
) | |||||||||||||||||||||||||||||||||||||||||
Deemed distribution to CCCIS option holders |
— |
— |
— |
— |
— |
— |
— |
— |
— |
( |
) |
— |
— |
( |
) | |||||||||||||||||||||||||||||||||||||||||
Company Vesting Shares granted to CCCIS stockholders |
— |
— |
— |
— |
— |
— |
— |
— |
— |
( |
) |
— |
— |
|||||||||||||||||||||||||||||||||||||||||||
Tax effect of Business Combination transaction costs |
— |
— |
— |
— |
— |
— |
— |
— |
— |
— |
— |
|||||||||||||||||||||||||||||||||||||||||||||
Foreign currency translation adjustment |
— |
— |
— |
— |
— |
— |
— |
— |
— |
— |
— |
( |
) |
( |
) | |||||||||||||||||||||||||||||||||||||||||
Net loss |
— |
— |
— |
— |
— |
— |
— |
— |
— |
— |
( |
) |
— |
( |
) | |||||||||||||||||||||||||||||||||||||||||
BALANCE—December 31, 2021 |
$ |
— |
$ |
— |
— |
$ |
— |
$ |
— |
$ |
$ |
$ |
( |
) |
$ |
( |
) |
$ |
||||||||||||||||||||||||||||||||||||||
2021 |
2020 |
2019 |
||||||||||
CASH FLOWS FROM OPERATING ACTIVITIES: |
||||||||||||
Net loss |
$ |
( |
) |
$ |
( |
) |
$ |
( |
) | |||
Adjustments to reconcile net loss to net cash provided by operating activities: |
||||||||||||
Depreciation and amortization of software, equipment, and property |
||||||||||||
Amortization of intangible assets |
||||||||||||
Impairment of goodwill and intangible assets |
— |
— |
||||||||||
Deferred income taxes |
( |
) |
( |
) |
( |
) | ||||||
Stock-based compensation |
||||||||||||
Amortization of deferred financing fees |
||||||||||||
Amortization of discount on debt |
||||||||||||
Change in fair value of interest rate swaps |
( |
) |
||||||||||
Change in fair value of warrant liabilities |
— |
— |
||||||||||
Loss on early extinguishment of debt |
— |
|||||||||||
Non-cash lease expense |
— |
— |
||||||||||
Gain on divestiture |
( |
) |
( |
) |
— |
|||||||
Other |
||||||||||||
Changes in: |
||||||||||||
Accounts receivable—Net |
( |
) |
( |
) |
( |
) | ||||||
Deferred contract costs |
( |
) |
( |
) |
( |
) | ||||||
Other current assets |
( |
) |
( |
) |
( |
) | ||||||
Deferred contract costs—Non-current |
( |
) |
( |
) |
( |
) | ||||||
Other assets |
( |
) |
( |
) |
( |
) | ||||||
Operating lease assets |
— |
— |
||||||||||
Income taxes |
( |
) | ||||||||||
Accounts payable |
( |
) |
( |
) |
||||||||
Accrued expenses |
||||||||||||
Operating lease liabilities |
( |
) |
— |
— |
||||||||
Deferred revenues |
||||||||||||
Extinguishment of interest rate swap liability |
( |
) |
— |
— |
||||||||
Other liabilities |
( |
) |
||||||||||
Net cash provided by operating activities |
||||||||||||
CASH FLOWS FROM INVESTING ACTIVITIES: |
||||||||||||
Purchases of software, equipment, and property |
( |
) |
( |
) |
( |
) | ||||||
Purchase of investment |
— |
— |
( |
) | ||||||||
Purchase of equity method investment |
( |
) |
— |
— |
||||||||
Purchase of intangible asset |
( |
) |
( |
) |
( |
) | ||||||
Net cash used in investing activities |
( |
) |
( |
) |
( |
) | ||||||
CASH FLOWS FROM FINANCING ACTIVITIES: |
||||||||||||
Principal payments on long-term debt |
( |
) |
( |
) |
( |
) | ||||||
Proceeds from issuance of long-term debt, net of fees paid to lender |
— |
|||||||||||
Payment of fees associated with early extinguishment of long-term debt |
( |
) |
( |
) |
— |
|||||||
Proceeds from borrowings on revolving lines of credit |
— |
— |
||||||||||
Repayment of borrowings on revolving lines of credit |
— |
( |
) |
— |
||||||||
Net proceeds from equity infusion from the Business Combination |
— |
— |
||||||||||
Dividends to CCCIS stockholders |
( |
) |
— |
— |
||||||||
Deemed distribution to CCCIS option holders |
( |
) |
— |
— |
||||||||
Tax effect of Business Combination transaction costs |
— |
— |
||||||||||
Proceeds from exercise of stock options |
( |
) |
||||||||||
Proceeds from issuance of common stock |
— |
|||||||||||
Repurchases of common stock |
— |
( |
) | |||||||||
Proceeds from issuance of non-controlling interest in subsidiary |
— |
— |
||||||||||
Net cash used in financing activities |
( |
) |
( |
) |
( |
) | ||||||
NET EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS |
( |
) | ||||||||||
NET CHANGE IN CASH AND CASH EQUIVALENTS |
||||||||||||
CASH AND CASH EQUIVALENTS: |
||||||||||||
Beginning of period |
||||||||||||
End of period |
$ |
$ |
$ |
|||||||||
NONCASH INVESTING AND FINANCING ACTIVITIES: |
||||||||||||
Unpaid liability related to software, equipment, and property |
$ |
$ |
$ |
|||||||||
Leasehold improvements acquired by tenant improvement allowance |
$ |
$ |
— |
$ |
— |
|||||||
Fair value of assumed common stock warrants exercised |
$ |
$ |
— |
$ |
— |
|||||||
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: |
||||||||||||
Cash paid for interest, excluding extinguishment of interest rate swap liability |
$ |
$ |
$ |
|||||||||
Cash (paid) received for income taxes—Net |
$ |
( |
) |
$ |
$ |
( |
) | |||||
1. |
ORGANIZATION AND NATURE OF OPERATIONS |
2. |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
Year Ended December 31, |
||||||||||||
2021 |
2020 |
2019 |
||||||||||
Customer A |
* | * | % | |||||||||
Customer B |
* | % | % |
* |
Below 10% |
• | Identification of the contract, or contracts, with a customer |
• | Identification of the performance obligation(s) in the contract |
• | Determination of the transaction price |
• | Allocation of the transaction price to the performance obligation(s) in the contract |
• | Recognition of revenue when, or as a performance obligation is satisfied |
Year Ended December 31, |
||||||||||||
2021 |
2020 |
2019 |
||||||||||
Software subscriptions |
|
$ |
|
|
$ |
|
|
$ |
| |||
Other |
|
|
|
|
|
|
|
|
| |||
Total revenues |
|
$ |
|
|
$ |
|
|
$ |
|
Software, equipment, and property |
Estimated Useful Life | |
Software and licenses | ||
Computer equipment | ||
Furniture and other equipment | ||
Database | ||
Building | ||
Leasehold improvements | ||
Land |
3. |
BUSINESS COMBINATION |
• | the pre-Closing CCCIS stockholders continue to control the Company following the Closing of the Business Combination; |
• | the board of directors and management of the Company following the Business Combination are composed of individuals associated with CCCIS; |
• | CCCIS was the larger entity based on historical operating activity, assets, revenues, and employee base at the time of the Closing of the Transactions; and |
• | the ongoing operations of the Company following the Business Combination comprise those of CCCIS. |
• | each share of CCCIS common stock that was issued and outstanding immediately prior to the Effective Time was automatically canceled and converted into the right to receive shares of the Company’s common stock based on the Exchange Ratio, rounded down to the nearest whole number of shares; |
• | each option to purchase shares of CCCIS common stock, whether vested or unvested, that was outstanding and unexercised as of immediately prior to the Effective Time was assumed by the Company and became an option (vested or unvested, as applicable) to purchase a number of shares of the Company’s common stock equal to the number of shares of CCCIS common stock subject to such option immediately prior to the Effective Time multiplied by the Exchange Ratio, rounded down to the nearest whole number of shares, at an exercise price equal to the exercise price per share of such option immediately prior to the Effective Time divided by the Exchange Ratio and rounded up to the nearest whole cent; |
• | each of Dragoneer’s redeemable Class A ordinary shares and Class B ordinary shares that was issued and outstanding immediately prior to the Effective Time was exchanged for an equal number of shares of the Company’s common stock. |
Shares issued to Dragoneer public shareholders and Sponsor |
||||
Sponsor Vesting Shares |
||||
Shares issued to Legacy CCC shareholders |
||||
Shares issued to Forward Purchasers |
||||
Shares issued to PIPE Investors |
||||
|
|
|||
Total shares of common stock outstanding immediately following the Business Combination |
||||
|
|
Cash - Dragoneer trust and cash |
$ | |
||
Cash - PIPE Financing |
||||
Cash - Forward Purchase Agreements |
||||
Less: transaction costs and advisory fees |
( |
) | ||
|
|
|||
Net cash contibutions from Business Combination |
||||
Less: non-cash fair value of Public Warrants and Private Warrants |
( |
) | ||
|
|
|||
Net equity infusion from Business Combination |
$ | |
||
|
|
4. |
REVENUE |
December 31, 2021 |
December 31, 2020 |
December 31, 2019 |
January 1, 2019 |
|||||||||||||
Accounts receivables-Net of allowances |
$ | |
$ | |
$ | |
$ | |
||||||||
Deferred contract costs |
||||||||||||||||
Long-term deferred contract costs |
||||||||||||||||
Deferred revenues |
||||||||||||||||
Other liabilities (deferred revenues, non-current) |
Year Ended December 31, |
||||||||||||
2021 |
2020 |
2019 |
||||||||||
Balance at beginning of period |
$ | $ | $ | |||||||||
Revenue recognized 1 |
( |
) | ( |
) | ( |
) | ||||||
Additional amounts deferred 1 |
||||||||||||
|
|
|
|
|
|
|||||||
Balance at end of period |
$ | $ | $ | |||||||||
|
|
|
|
|
|
|||||||
Classified as: |
||||||||||||
Current |
$ | $ | $ | |||||||||
Non-current |
||||||||||||
|
|
|
|
|
|
|||||||
Total deferred revenue |
$ | $ | $ | |||||||||
|
|
|
|
|
|
1 |
Amounts include total revenue deferred and recognized during each respective period. |
Year Ended December 31, |
||||||||||||
2021 |
2020 |
2019 |
||||||||||
Balance at beginning of period |
$ | $ | $ | |||||||||
Adoption of ASC 606 |
||||||||||||
Costs amortized |
( |
) | ( |
) | ( |
) | ||||||
Additional amounts deferred |
||||||||||||
|
|
|
|
|
|
|||||||
Balance at end of period |
$ | $ | $ | |
||||||||
|
|
|
|
|
|
|||||||
Classified as: |
||||||||||||
Current |
$ | $ | $ | |||||||||
Non-current |
||||||||||||
|
|
|
|
|
|
|||||||
Total deferred contract costs |
$ | $ | $ | |||||||||
|
|
|
|
|
|
5. |
FAIR VALUE MEASUREMENTS |
Expected term (in years) |
||||
Expected volatility |
% | |||
Expected dividend yield |
% | |||
Risk-free interest rate |
% | |||
Fair value at valuation date |
$ | |
Liabilities |
Fair Value |
Level 1 |
Level 2 |
Level 3 |
||||||||||||
Private Warrants |
$ | |
$ | — | $ | |
$ | |
||||||||
|
|
|
|
|
|
|
|
|||||||||
Total |
$ | $ | $ | $ | ||||||||||||
|
|
|
|
|
|
|
|
Liabilities |
Fair Value |
Level 1 |
Level 2 |
Level 3 |
||||||||||||
Interest rate swaps |
$ | |
$ | |
$ | |
$ | |
||||||||
|
|
|
|
|
|
|
|
|||||||||
Total |
$ | $ | $ | $ | ||||||||||||
|
|
|
|
|
|
|
|
December 31, 2021 |
December 31, 2020 |
|||||||||||||||
Description |
Carrying Amount |
Estimated Fair Value |
Carrying Amount |
Estimated Fair Value |
||||||||||||
Term B Loan, including current portion |
$ | |
$ | |
$ | — | $ | — | ||||||||
First Lien Term Loan, including current portion |
— | — |
6. |
INCOME TAXES |
Year Ended December 31, |
||||||||||||
2021 |
2020 |
2019 |
||||||||||
Domestic |
$ | ( |
) | $ | ( |
) | $ | ( |
) | |||
Foreign |
( |
) | ( |
) | ( |
) | ||||||
|
|
|
|
|
|
|||||||
Pretax loss |
$ | ( |
) | $ | ( |
) | $ | ( |
) | |||
|
|
|
|
|
|
Year Ended December 31, |
||||||||||||
2021 |
2020 |
2019 |
||||||||||
Current provision (benefit): |
||||||||||||
Federal |
$ | $ | $ | |||||||||
State |
||||||||||||
|
|
|
|
|
|
|||||||
Total current provision |
||||||||||||
|
|
|
|
|
|
|||||||
Deferred provision (benefit): |
||||||||||||
Federal |
( |
) | ( |
) | ( |
) | ||||||
State |
( |
) | ( |
) | ( |
) | ||||||
Foreign |
( |
) | ( |
) | ( |
) | ||||||
Change in valuation allowance |
||||||||||||
|
|
|
|
|
|
|||||||
Total deferred benefit |
( |
) | ( |
) | ( |
) | ||||||
|
|
|
|
|
|
|||||||
Total income tax benefit |
$ | ( |
) | $ | ( |
) | $ | ( |
) | |||
|
|
|
|
|
|
Year Ended December 31, |
||||||||||||||||||||||||
2021 |
2020 |
2019 |
||||||||||||||||||||||
Federal income tax benefit at statutory rate |
$ | ( |
) | % | $ | ( |
) | % | $ | ( |
) | % | ||||||||||||
State and local taxes-net of federal income tax effect |
( |
) | ( |
) | ( |
) | ||||||||||||||||||
Impairment of goodwill |
— | — | ( |
) | ||||||||||||||||||||
Foreign rate difference |
( |
) | ( |
) | ( |
) | ||||||||||||||||||
Research and experimental credit |
( |
) | ( |
) | ( |
) | ||||||||||||||||||
Other nondeductible expenses |
( |
) | ( |
) | ( |
) | ||||||||||||||||||
Stock-based compensation |
( |
) | ( |
) | ( |
) | ||||||||||||||||||
Uncertain tax positions |
( |
) | ( |
) | ( |
) | ||||||||||||||||||
Valuation allowance |
( |
) | ( |
) | ( |
) | ||||||||||||||||||
Fair value of warrants |
( |
) | — | — | ||||||||||||||||||||
Executive compensation |
( |
) | — | — | ||||||||||||||||||||
Other—net |
( |
) | ( |
) | ( |
) | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Income tax benefit |
$ | ( |
) | % | $ | ( |
) | % | $ | ( |
) | % | ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, |
||||||||
2021 |
2020 |
|||||||
Deferred income tax assets: |
||||||||
Stock-based compensation |
$ | $ | ||||||
Operating lease liabilities |
— | |||||||
Net operating losses—foreign |
||||||||
Accrued compensation |
||||||||
Disallowed interest expense |
||||||||
Research and experimental credit |
||||||||
Sales allowances and doubtful accounts |
||||||||
Net operating losses—domestic (state) |
||||||||
Interest rate swaps |
— | |||||||
Other |
||||||||
|
|
|
|
|||||
Total deferred income tax assets |
||||||||
Valuation allowance for deferred tax asset |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Net deferred income tax assets |
||||||||
|
|
|
|
|||||
Deferred income tax liabilities: |
||||||||
Intangible asset amortization |
||||||||
Software, equipment and property depreciation and amortization |
||||||||
Deferred contract costs |
||||||||
Operating lease assets |
— | |||||||
|
|
|
|
|||||
Total deferred income tax liabilities |
||||||||
|
|
|
|
|||||
Net deferred income tax liabilities |
$ | |
$ | |
||||
|
|
|
|
2021 |
2020 |
|||||||
Balance at beginning of year |
$ | |
$ | |
||||
Additions based on tax positions related to the current year |
||||||||
Additions based on adjustments to tax positions related to prior years |
||||||||
Reductions for tax positions of prior years |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Balance at end of year |
$ | $ | ||||||
|
|
|
|
Jurisdiction |
Open Tax Years |
|||
US Federal |
||||
US States |
||||
China |
||||
Canada |
7. |
ACCOUNTS RECEIVABLE |
December 31, |
||||||||
2021 |
2020 |
|||||||
Accounts receivable |
$ | |
$ | |
||||
Allowance for doubtful accounts and sales reserves |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Accounts receivable–net |
$ | $ | ||||||
|
|
|
|
Year Ended December 31, |
||||||||||||
2021 |
2020 |
2019 |
||||||||||
Balance at beginning of period |
$ | $ | $ | |||||||||
Charges to bad debt and sales reserves |
||||||||||||
Write-offs, net |
( |
) | ( |
) | ( |
) | ||||||
|
|
|
|
|
|
|||||||
Balance at end of period |
$ | $ | $ | |||||||||
|
|
|
|
|
|
8. |
OTHER CURRENT ASSETS |
December 31, |
||||||||
2021 |
2020 |
|||||||
Prepaid service fees |
$ | $ | ||||||
Non-trade receivables |
||||||||
Prepaid software and equipment maintenance |
||||||||
Prepaid SaaS costs |
||||||||
Prepaid insurance |
||||||||
Other |
||||||||
|
|
|
|
|||||
Total |
$ | |
$ | |
||||
|
|
|
|
9. |
SOFTWARE, EQUIPMENT, AND PROPERTY |
December 31, |
||||||||
2021 |
2020 |
|||||||
Software, licenses and database |
$ | |
$ | |
||||
Leasehold improvements |
||||||||
Computer equipment |
||||||||
Furniture and other equipment |
||||||||
Building and land |
||||||||
|
|
|
|
|||||
Total software, equipment, and property |
||||||||
Less accumulated depreciation and amortization |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Net software, equipment, and property |
$ | $ | ||||||
|
|
|
|
10. |
LEASES |
Year Ended December 31, 2021 |
||||
Operating lease costs |
$ | |
||
Variable lease costs |
||||
|
|
|||
Total lease costs |
$ | |||
|
|
Weighted-average remaining lease term (years) |
||||
Weighted-average discount rate |
% |
Year Ended December 31, 2021 |
||||
Cash payments for operating leases |
$ | |
||
Operating lease assets obtained in exchange for lease liabilities |
Years Ending December 31: |
2022 |
$ | |||
2023 |
||||
2024 |
||||
2025 |
||||
2026 |
||||
Thereafter |
||||
|
|
|||
Total Lease Payments |
||||
Less: Interest |
( |
) | ||
Total |
$ | |||
|
|
Years Ending December 31: |
||||
2021 |
$ | |||
2022 |
||||
2023 |
||||
2024 |
||||
2025 |
||||
Thereafter |
||||
|
|
|||
Total |
$ | |
||
|
|
11. |
GOODWILL AND INTANGIBLE ASSETS |
Reconciliation of goodwill carrying amount |
Cost |
Accumulated Impairment Loss |
Net Carrying Value |
|||||||||
Balance as of December 31, 2021 |
$ | |
$ | ( |
) | $ | |
|||||
Balance as of December 31, 2020 |
( |
) | ||||||||||
Balance as of December 31, 2019 |
( |
) |
Estimated Useful Life (Years) |
Weighted- Average Remaining Useful Life (Years) |
Gross Carrying Amount |
Accumulated Amortization |
Net Carrying Amount |
||||||||||||||||
Intangible assets: |
||||||||||||||||||||
Customer relationships |
$ | |
$ | ( |
) | $ | ||||||||||||||
Acquired technologies |
( |
) | ||||||||||||||||||
Favorable lease terms |
( |
) | ||||||||||||||||||
|
|
|
|
|
|
|||||||||||||||
Subtotal |
( |
) | ||||||||||||||||||
Trademarks—indefinite life |
— | |||||||||||||||||||
|
|
|
|
|
|
|||||||||||||||
Total intangible assets |
$ | $ | ( |
) | $ | |
||||||||||||||
|
|
|
|
|
|
Estimated Useful Life (Years) |
Weighted- Average Remaining Useful Life (Years) |
Gross Carrying Amount |
Accumulated Amortization |
Net Carrying Amount |
||||||||||||||||
Intangible assets: |
||||||||||||||||||||
Customer relationships |
$ | |
$ | ( |
) | $ | |
|||||||||||||
Acquired technologies |
( |
) | ||||||||||||||||||
Favorable lease terms |
( |
) | ||||||||||||||||||
|
|
|
|
|
|
|||||||||||||||
Subtotal |
( |
) | ||||||||||||||||||
Trademarks—indefinite life |
— | |||||||||||||||||||
|
|
|
|
|
|
|||||||||||||||
Total intangible assets |
$ | $ | ( |
) | $ | |||||||||||||||
|
|
|
|
|
|
Years Ending December 31: |
||||
2022 |
$ | |||
2023 |
||||
2024 |
||||
2025 |
||||
2026 |
||||
Thereafter |
||||
|
|
|||
Total |
$ | |
||
|
|
12. |
EQUITY METHOD INVESTMENT |
Equity method investment carrying value at December 31, 2020 |
$ | |||
Cash contributions |
||||
Share of net income (loss) from the Investee |
— | |||
|
|
|||
Equity method investment carrying value at December 31, 2021 |
$ | |
||
|
|
13. |
ACCRUED EXPENSES |
December 31, |
||||||||
2021 |
2020 |
|||||||
Compensation |
$ | |
$ | |
||||
Software license agreements |
||||||||
Royalties and licenses |
||||||||
Employee insurance benefits |
||||||||
Professional services |
||||||||
Sales tax |
||||||||
Other |
||||||||
Total |
$ | $ | ||||||
14. |
OTHER LIABILITIES |
December 31, |
||||||||
2021 |
2020 |
|||||||
Software license agreements |
$ | |
$ | |||||
Deferred revenue-non-current |
||||||||
Fair value of interest rate swaps |
||||||||
Deferred rent |
||||||||
Phantom stock incentive plan |
||||||||
Payroll tax deferment |
||||||||
Other |
||||||||
Total |
$ | $ | |
|||||
15. |
LONG-TERM DEBT |
(1) |
a base rate determined by reference to the highest of (a) the rate last quoted by the Wall Street Journal as the “prime rate,” (b) the federal funds effective rate plus |
(2) |
a Eurocurrency rate determined by reference to LIBOR (other than with respect to Euros, Euribor and with respect to British Pounds Sterling, SONIA) with a term as selected by the Company, of one, three or six months (subject to (x) in the case of term loans, a |
December 31, |
||||||||
2021 |
2020 |
|||||||
Term B Loan |
$ | |
$ | — | ||||
Term B Loan—discount |
( |
) | — | |||||
Term B Loan—deferred financing fees |
( |
) | — | |||||
Term B Loan—net of discount & fees |
— | |||||||
First Lien Term Loan |
— | |||||||
First Lien Term Loan—discount |
— | ( |
) | |||||
First Lien Term Loan—deferred financing fees |
— | ( |
) | |||||
First Lien Term Loan—net of discount & fees |
— | |||||||
Less: Current portion |
( |
) | ( |
) | ||||
Total long-term debt—net of current portion |
$ | $ | |
|||||
Deferred |
Discount— |
|||||||
Financing |
Contra |
|||||||
Fees |
Debt |
|||||||
Balance—December 31, 2019 |
$ | $ | ||||||
Fees written off of due to early extinguishment of debt |
( |
) | ( |
) | ||||
Payment of fees and discount |
||||||||
Amortization of fees and discount |
( |
) | ( |
) | ||||
Balance—December 31, 2020 |
||||||||
Fees written off of due to early extinguishment of debt |
( |
) | ( |
) | ||||
Payment of fees and discount |
||||||||
Amortization of fees and discount |
( |
) | ( |
) | ||||
Balance—December 31, 2021 |
$ | $ | ||||||
Years Ending December 31: |
||||
2022 |
$ | |||
2023 |
||||
2024 |
||||
2025 |
||||
2026 |
||||
Thereafter |
||||
Total |
$ | |
||
16. |
LONG-TERM LICENSING AGREEMENT |
Years Ending December 31: |
||||
2022 |
$ | |||
2023 |
||||
2024 |
||||
2025 |
||||
2026 |
||||
Thereafter |
||||
Total |
$ | |
||
17. |
REDEEMABLE NON-CONTROLLING INTEREST |
18. |
CAPITAL STOCK |
19. |
EMPLOYEE BENEFIT PLANS |
20. |
STOCK INCENTIVE PLANS |
Stock options outstanding |
||||
Restricted stock units outstanding |
||||
Restricted stock units available for future grant |
||||
Reserved for Employee Stock Purchase Plan |
||||
Common stock reserved for future issuance |
||||
2021 |
2020 |
2019 |
||||||||||
Expected term (in years) |
||||||||||||
Expected volatility |
% | % | % | |||||||||
Expected dividend yield |
% | % | % | |||||||||
Risk-free interest rate |
% | % | % | |||||||||
Fair value at valuation date |
$ | $ | $ |
2021 |
2020 |
2019 |
||||||||||
Expected term (in years) |
||||||||||||
Expected volatility |
% | % | % | |||||||||
Expected dividend yield |
% | % | % | |||||||||
Risk-free interest rate |
% | % | % | |||||||||
Fair value at valuation date |
$ | $ | $ |
Shares |
Weighted- Average Exercise Price |
Weighted-Average Remaining Contractual Life (in years) |
Aggregate Intrinsic Value (in thousands) |
|||||||||||||
Options outstanding—December 31, 2018 |
$ | |
$ | |||||||||||||
Granted |
||||||||||||||||
Exercised |
( |
) | ||||||||||||||
Forfeited and canceled |
( |
) | ||||||||||||||
Options outstanding—December 31, 2019 |
||||||||||||||||
Granted |
||||||||||||||||
Exercised |
( |
) | ||||||||||||||
Forfeited and canceled |
( |
) | ||||||||||||||
Options outstanding—December 31, 2020 |
||||||||||||||||
Granted |
||||||||||||||||
Exercised |
( |
) | ||||||||||||||
Forfeited and canceled |
( |
) | ||||||||||||||
Options outstanding—December 31, 2021 |
$ | $ | |
|||||||||||||
Options exercisable—December 31, 2021 |
$ | $ | ||||||||||||||
Options vested and expected to vest—December 31, 2021 |
$ | $ | ||||||||||||||
Shares |
Weighted- Average Fair Value |
|||||||
Non-vested RSUs—December 31, 2020 |
$ | |||||||
Granted |
||||||||
Canceled |
( |
) | ||||||
Non-vested RSUs—December 31, 2021 |
$ | |
||||||
Year Ended December 31, |
||||||||||||
2021 |
2020 |
2019 |
||||||||||
Cost of revenues |
$ | $ | $ | |||||||||
Research and development |
||||||||||||
Sales and marketing |
||||||||||||
General and administrative |
||||||||||||
Total stock-based compensation expense |
$ | |
$ | |
$ | |
||||||
21. |
WARRANTS |
• | at a price of $ |
• | upon a minimum of 30 days prior written notice of redemption to each warrant holder; and |
• | if, and only if, the closing price of the Company’s common shares equals or exceeds $18.00 per share (as adjusted) on the trading day prior to the date on which the Company sends the notice of redemption to the warrant holders. |
• | at a price of $ |
• | upon a minimum of 30 days prior written notice of redemption provided holders will be able to exercise their warrants on a “cashless basis” prior to redemption and receive that number of shares determined by reference to an agreed table based on the redemption date and the fair market value of the Company’s common stock; and |
• | if, and only if, the closing price of the Company’s common stock equals or exceeds $10.00 per share (as adjusted) on the trading day prior to the date on which the Company sends the notice of redemption to the warrant holders. |
22. |
COMMITMENTS |
Years Ending December 31: |
||||
2022 |
$ | |||
2023 |
||||
2024 |
||||
2025 |
||||
2026 |
||||
Thereafter |
||||
Total |
$ | |
||
23. |
LEGAL PROCEEDINGS AND CONTINGENCIES |
24. |
RELATED PARTIES |
25. |
NET LOSS PER SHARE |
Year Ended December 31, |
||||||||||||
2021 |
2020 |
2019 |
||||||||||
Numerator |
||||||||||||
Net loss |
$ | ( |
) | $ | ( |
) | $ | ( |
) | |||
Denominator |
||||||||||||
Weighted average shares of common stock—basic and diluted |
||||||||||||
Net loss per share - basic and diluted |
$ | ( |
) | $ | ( |
) | $ | ( |
) |
26. |
SEGMENT INFORMATION AND INFORMATION ABOUT GEOGRAPHIC AREAS |
Year Ended December 31, |
||||||||||||
2021 |
2020 |
2019 |
||||||||||
United States |
$ | |
$ | |
$ | |
||||||
China |
||||||||||||
Total revenues |
$ | $ | $ | |||||||||
December 31, |
||||||||
2021 |
2020 |
|||||||
United States |
$ | |
$ | |
||||
China |
||||||||
Total software, equipment and property-net |
$ | $ | ||||||
27. |
DIVESTITURE |
28. |
QUARTERLY RESULTS OF OPERATIONS (UNAUDITED) |
For the Quarter Ended |
||||||||||||||||
(in thousands, except per share data) |
||||||||||||||||
March 31 2021 |
June 30 2021 |
September 30, 2021 |
December 31, 2021 |
|||||||||||||
Revenue |
$ | |
$ | |
$ | $ | |
|||||||||
Cost of revenue |
||||||||||||||||
Gross Profit |
||||||||||||||||
Income (loss) from operations |
( |
) | ||||||||||||||
Net (loss) income |
( |
) | ( |
) | ( |
) | ||||||||||
Net (loss) income per share: |
||||||||||||||||
Basic |
$ | ( |
) | $ | $ | ( |
) | $ | ( |
) | ||||||
Diluted |
$ | ( |
) | $ | $ | ( |
) | $ | ( |
) |
For the Quarter Ended |
||||||||||||||||
(in thousands, except per share data) |
||||||||||||||||
March 31 2020 |
June 30 2020 |
September 30, 2020 |
December 31, 2020 |
|||||||||||||
Revenue |
$ | |
$ | |
$ | |
$ | |
||||||||
Cost of revenue |
||||||||||||||||
Gross Profit |
||||||||||||||||
Income (loss) from operations |
||||||||||||||||
Net (loss) income |
( |
) | ( |
) | ||||||||||||
Net (loss) income per share: |
||||||||||||||||
Basic |
$ | ( |
) | $ | ( |
) | $ | $ | ||||||||
Diluted |
$ | ( |
) | $ | ( |
) | $ | $ |
29. |
SUBSEQUENT EVENTS |
March 31, 2022 |
December 31, 2021 |
|||||||
(Unaudited) |
||||||||
ASSETS |
||||||||
CURRENT ASSETS: |
||||||||
Cash and cash equivalents |
$ | $ | ||||||
Accounts receivable—Net of allowances of $ |
||||||||
Income taxes receivable |
||||||||
Deferred contract costs |
||||||||
Other current assets |
||||||||
Total current assets |
||||||||
SOFTWARE, EQUIPMENT, AND PROPERTY—Net |
||||||||
OPERATING LEASE ASSETS |
||||||||
INTANGIBLE ASSETS—Net |
||||||||
GOODWILL |
||||||||
DEFERRED FINANCING FEES, REVOLVER—Net |
||||||||
DEFERRED CONTRACT COSTS |
||||||||
EQUITY METHOD INVESTMENT |
||||||||
OTHER ASSETS |
||||||||
TOTAL |
$ | $ | ||||||
LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY |
||||||||
CURRENT LIABILITIES: |
||||||||
Accounts payable |
$ | $ | ||||||
Accrued expenses |
||||||||
Income taxes payable |
||||||||
Current portion of long-term debt |
||||||||
Current portion of long-term licensing agreement—Net |
||||||||
Operating lease liabilities |
||||||||
Deferred revenues |
||||||||
Total current liabilities |
||||||||
LONG-TERM DEBT—Net |
||||||||
DEFERRED INCOME TAXES—Net |
||||||||
LONG-TERM LICENSING AGREEMENT—Net |
||||||||
OPERATING LEASE LIABILITIES |
||||||||
WARRANT LIABILITIES |
||||||||
OTHER LIABILITIES |
||||||||
Total liabilities |
||||||||
COMMITMENTS AND CONTINGENCIES (Notes 19 and 20) |
||||||||
MEZZANINE EQUITY: |
||||||||
Redeemable non-controlling interest |
||||||||
STOCKHOLDERS’ EQUITY: |
||||||||
Preferred stock—$ |
||||||||
Common stock—$ |
||||||||
Additional paid-in capital |
||||||||
Accumulated deficit |
( |
) | ( |
) | ||||
Accumulated other comprehensive loss |
( |
) | ( |
) | ||||
Total stockholders’ equity |
||||||||
TOTAL |
$ | $ | ||||||
For the Three Months Ended March 31, |
||||||||
2022 |
2021 |
|||||||
REVENUES |
$ | $ | ||||||
COST OF REVENUES |
||||||||
Cost of revenues, exclusive of amortization of acquired technologies |
||||||||
Amortization of acquired technologies |
||||||||
Total cost of revenues |
||||||||
GROSS PROFIT |
||||||||
OPERATING EXPENSES: |
||||||||
Research and development |
||||||||
Selling and marketing |
||||||||
General and administrative |
||||||||
Amortization of intangible assets |
||||||||
Total operating expenses |
||||||||
OPERATING INCOME |
||||||||
INTEREST EXPENSE |
( |
) | ( |
) | ||||
GAIN ON CHANGE IN FAIR VALUE OF INTEREST RATE SWAPS |
||||||||
GAIN ON SALE OF COST METHOD INVESTMENT |
||||||||
CHANGE IN FAIR VALUE OF WARRANT LIABILITIES |
||||||||
OTHER INCOME—Net |
||||||||
PRETAX INCOME (LOSS) |
( |
) | ||||||
INCOME TAX BENEFIT |
||||||||
NET INCOME (LOSS) INCLUDING NON-CONTROLLING INTEREST |
( |
) | ||||||
Less: net income (loss) attributable to non-controlling interest |
||||||||
NET INCOME (LOSS) ATTRIBUTABLE TO CCC INTELLIGENT SOLUTIONS HOLDINGS INC. |
$ | $ | ( |
) | ||||
Net income (loss) per share attributable to common stockholders: |
||||||||
Basic |
$ | $ | ( |
) | ||||
Diluted |
$ | $ | ( |
) | ||||
Weighted-average shares used in computing net income (loss) per share attributable to common stockholders: |
||||||||
Basic |
||||||||
Diluted |
||||||||
COMPREHENSIVE INCOME (LOSS): |
||||||||
Net income (loss) including non-controlling interest |
( |
) | ||||||
Other comprehensive income—Foreign currency translation adjustment |
||||||||
COMPREHENSIVE INCOME (LOSS) INCLUDING NON-CONTROLLING INTEREST |
( |
) | ||||||
Less: comprehensive income (loss) attributable to non-controlling interest |
||||||||
COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO CCC INTELLIGENT SOLUTIONS HOLDINGS INC. |
$ | $ | ( |
) | ||||
Redeemable Non-Controlling Interest |
Issued Preferred Stock |
Common Stock |
Additional Paid-In Capital |
Accumulated Deficit |
Accumulated Other Comprehensive Loss |
Total Stockholders’ Equity |
||||||||||||||||||||||||||||||
Number of Shares |
Par Value |
Number of Shares |
Par Value |
|||||||||||||||||||||||||||||||||
BALANCE—December 31, 2021 |
$ | — | $ | — | $ | $ | $ | ( |
) | $ | ( |
) | $ | |||||||||||||||||||||||
Stock-based compensation expense |
— | — | — | — | — | — | — | |||||||||||||||||||||||||||||
Exercise of stock options—net of tax |
— | — | — | — | — | — | ||||||||||||||||||||||||||||||
Exercise of warrants—net |
— | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||
Issuance of common stock upon vesting of RSUs—net of tax |
— | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||
Foreign currency translation adjustment |
— | — | — | — | — | — | — | |||||||||||||||||||||||||||||
Net income |
— | — | — | — | — | — | — | |||||||||||||||||||||||||||||
BALANCE—March 31, 2022 |
$ | — | $ | — | $ | $ | $ | ( |
) | $ | ( |
) | $ | |||||||||||||||||||||||
Redeemable Non-Controlling Interest |
Issued Preferred Stock |
Common Stock |
Additional Paid-In Capital |
Accumulated Deficit |
Accumulated Other Comprehensive Loss |
Total Stockholders’ Equity |
||||||||||||||||||||||||||||||
Number of Shares |
Par Value |
Number of Shares |
Par Value |
|||||||||||||||||||||||||||||||||
BALANCE—December 31, 2020 |
$ | — | $ | — | $ | $ | ( |
) | $ | ( |
) | $ | ||||||||||||||||||||||||
Issuance of common stock |
— | — | — | — | — | — | ||||||||||||||||||||||||||||||
Stock-based compensation expense |
— | — | — | — | — | — | ||||||||||||||||||||||||||||||
Exercise of stock options—net of tax |
— | — | — | — | — | — | ||||||||||||||||||||||||||||||
Dividend to CCCIS stockholders |
— | — | — | — | — | — | ( |
) | — | ( |
) | |||||||||||||||||||||||||
Foreign currency translation adjustment |
— | — | — | — | — | — | — | |||||||||||||||||||||||||||||
Net loss |
— | — | — | — | — | — | ( |
) | — | ( |
) | |||||||||||||||||||||||||
BALANCE—March 31, 2021 |
$ | — | $ | — | $ | $ | $ | ( |
) | $ | ( |
) | $ | |||||||||||||||||||||||
For the Three Months Ended March 31, |
||||||||
2022 |
2021 |
|||||||
CASH FLOWS FROM OPERATING ACTIVITIES: |
||||||||
Net income (loss) |
$ | $ | ( |
) | ||||
Adjustments to reconcile net loss to net cash provided by operating activities: |
||||||||
Depreciation and amortization of software, equipment, and property |
||||||||
Amortization of intangible assets |
||||||||
Deferred income taxes |
( |
) | ( |
) | ||||
Stock-based compensation |
||||||||
Amortization of deferred financing fees |
||||||||
Amortization of discount on debt |
||||||||
Change in fair value of interest rate swaps |
( |
) | ||||||
Change in fair value of warrant liabilities |
( |
) | — | |||||
Non-cash lease expense |
||||||||
Loss on disposal of software, equipment and property |
||||||||
Gain on sale of cost method investment |
( |
) | ||||||
Other |
||||||||
Changes in: |
||||||||
Accounts receivable—Net |
||||||||
Deferred contract costs |
( |
) | ||||||
Other current assets |
( |
) | ||||||
Deferred contract costs—Non-current |
( |
) | ||||||
Other assets |
( |
) | ||||||
Operating lease assets |
||||||||
Income taxes |
( |
) | ||||||
Accounts payable |
||||||||
Accrued expenses |
( |
) | ( |
) | ||||
Operating lease liabilities |
( |
) | ( |
) | ||||
Deferred revenues |
||||||||
Other liabilities |
( |
) | ( |
) | ||||
Net cash provided by operating activities |
||||||||
CASH FLOWS FROM INVESTING ACTIVITIES: |
||||||||
Purchases of software, equipment, and property |
( |
) | ( |
) | ||||
Acquisition of Safekeep, Inc., net of cash acquired |
( |
) | ||||||
Proceeds from sale of cost method investment |
||||||||
Purchase of intangible asset |
( |
) | ||||||
Net cash used in investing activities |
( |
) | ( |
) | ||||
CASH FLOWS FROM FINANCING ACTIVITIES: |
||||||||
Dividend to CCCIS stockholders |
( |
) | ||||||
Principal payments on long-term debt |
( |
) | ( |
) | ||||
Proceeds from issuance of common stock |
||||||||
Proceeds from exercise of stock options |
||||||||
Net cash provided by (used in) financing activities |
( |
) | ||||||
NET EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS |
||||||||
NET CHANGE IN CASH AND CASH EQUIVALENTS |
( |
) | ||||||
CASH AND CASH EQUIVALENTS: |
||||||||
Beginning of period |
||||||||
End of period |
$ | $ | ||||||
NONCASH INVESTING AND FINANCING ACTIVITIES: |
||||||||
Unpaid liability related to software, equipment, and property |
$ | $ | ||||||
Contingent consideration related to business acquisition |
$ | $ | ||||||
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: |
||||||||
Cash paid for interest |
$ | $ | ||||||
Cash received (paid) for income taxes—Net |
$ | $ | ( |
) | ||||
1. |
ORGANIZATION AND NATURE OF OPERATIONS |
2. |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
• | Identification of the c ontract, or contracts, with a customer |
• | Identification of the performance obligation(s) in the contract |
• | Determination of the transaction price |
• | Allocation of the transaction price to the performance obligation(s) in the contrac t |
• | Recognition of revenue when, or as a performance obligation is satisfied |
For the Three Months Ended March 31, |
||||||||
2022 |
2021 |
|||||||
Software subscriptions |
$ | $ | ||||||
Other |
||||||||
Total revenues |
$ | $ | ||||||
3. |
BUSINESS COMBINATION |
• | each share of CCCIS common stock that was issued and outstanding immediately prior to the Effective Time was automatically canceled and converted into the right to receive shares of the Company’s common stock based on the Exchange Ratio, rounded down to the nearest whole number of shares; |
• | each option to purchase shares of CCCIS common stock, whether vested or unvested, that was outstanding and unexercised as of immediately prior to the Effective Time was assumed by the Company and became an option (vested or unvested, as applicable) to purchase a number of shares of the Company’s common stock equal to the number of shares of CCCIS common stock subject to such option immediately prior to the Effective Time multiplied by the Exchange Ratio, rounded down to the nearest whole number of shares, at an exercise price equal to the exercise price per share of such option immediately prior to the Effective Time divided by the Exchange Ratio and rounded up to the nearest whole cent; |
• | each of Dragoneer’s redeemable Class A ordinary share and Class B ordinary share that was issued and outstanding immediately prior to the Effective Time was exchanged for an equal number of shares of the Company’s common stock. |
4. |
BUSINESS ACQUISITION |
Cash paid through closing |
$ | |||
Fair value of contingent earnout consideration |
||||
Total acquisition date fair value of the consideration transferred |
$ | |||
Assets acquired: |
||||
Current assets |
$ | |||
Intangible asset—acquired technology |
||||
Deferred tax assets |
||||
Total assets acquired |
||||
Liabilities assumed: |
||||
Current liabilities |
||||
Total liabilities assumed |
||||
Net assets acquired |
||||
Goodwill |
||||
Total purchase price |
$ | |||
5. |
REVENUE |
March 31, 2022 |
December 31, 2021 |
|||||||
Accounts receivables-net of allowances |
$ | $ | ||||||
Deferred contract costs |
||||||||
Long-term deferred contract costs |
||||||||
Other assets (accounts receivable, non-current) |
||||||||
Deferred revenues |
||||||||
Other liabilities (deferred revenues, non-current) |
For the Three Months Ended March 31, |
||||||||
2022 |
2021 |
|||||||
Balance at beginning of period |
$ | 5 | $ | |||||
Revenue recognized 1 |
( |
) | ( |
) | ||||
Additional amounts deferred 1 |
||||||||
Balance at end of period |
$ | $ | ||||||
Classified as: |
||||||||
Current |
$ | $ | ||||||
Non-current |
||||||||
Total deferred revenue |
$ | $ | ||||||
1 | Amounts include total revenue deferred and recognized during each respective period. |
For the Three Months Ended March 31, |
||||||||
2022 |
2021 |
|||||||
Balance at beginning of period |
$ | $ | ||||||
Costs amortized |
( |
) | ( |
) | ||||
Additional amounts deferred |
||||||||
Balance at end of period |
$ | $ | ||||||
Classified as: |
||||||||
Current |
$ | $ | ||||||
Non-current |
||||||||
Total deferred contract costs |
$ | $ | ||||||
6. |
FAIR VALUE MEASUREMENTS |
Expected term (in years) |
||||
Expected volatility |
% | |||
Expected dividend yield |
% | |||
Risk-free interest rate |
% | |||
Fair value at valuation date |
$ |
Liabilities |
Fair Value |
Level 1 |
Level 2 |
Level 3 |
||||||||||||
Contingent consideration related to business acquisition |
$ | $ | $ | $ | ||||||||||||
Private warrants |
||||||||||||||||
Total |
$ | $ | $ | $ | ||||||||||||
Liabilities |
Fair Value |
Level 1 |
Level 2 |
Level 3 |
||||||||||||
Private warrants |
$ | $ | $ | $ | ||||||||||||
Total |
$ | $ | $ | $ | ||||||||||||
March 31, 2022 |
December 31, 2021 |
|||||||||||||||
Description |
Carrying Amount |
Estimated Fair Value |
Carrying Amount |
Estimated Fair Value |
||||||||||||
Term B Loan, including current portion |
$ | $ | $ | $ |
7. |
INCOME TAXES |
8. |
ACCOUNTS RECEIVABLE |
March 31, 2022 |
December 31, 2021 |
|||||||
Accounts receivable |
$ | $ | ||||||
Allowance for doubtful accounts and sales reserves |
( |
) | ( |
) | ||||
Accounts receivable—net |
$ | $ | ||||||
For the Three Months Ended March 31, |
||||||||
2022 |
2021 |
|||||||
Balance at beginning of period |
$ | $ | ||||||
Charges to bad debt and sales reserves |
||||||||
Write-offs, net |
( |
) | ( |
) | ||||
Balance at end of period |
$ | $ | ||||||
9. |
OTHER CURRENT ASSETS |
March 31, 2022 |
December 31, 2021 |
|||||||
Non-trade receivables |
$ | $ | ||||||
Prepaid service fees |
||||||||
Prepaid software and equipment maintenance |
||||||||
Prepaid SaaS costs |
||||||||
Prepaid insurance |
||||||||
Other |
||||||||
Total |
$ | $ | ||||||
10. |
SOFTWARE, EQUIPMENT, AND PROPERTY |
March 31, 2022 |
December 31, 2021 |
|||||||
Software, licenses and database |
$ | $ | ||||||
Leasehold improvements |
||||||||
Computer equipment |
||||||||
Furniture and other equipment |
||||||||
Building and land |
||||||||
Total software, equipment, and property |
||||||||
Less accumulated depreciation and amortization |
( |
) | ( |
) | ||||
Net software, equipment, and property |
$ | $ | ||||||
11. |
LEASES |
For the Three Months Ended March 31, |
||||||||
2022 |
2021 |
|||||||
Operating lease costs |
$ | $ | ||||||
Variable lease costs |
||||||||
Total lease costs |
$ | $ | ||||||
For the Three Months Ended March 31, |
||||||||
2022 |
2021 |
|||||||
Cash payments for operating leases |
$ | $ | ||||||
Operating lease assets obtained in exchange for lease liabilities |
12. |
GOODWILL AND INTANGIBLE ASSETS |
Cost |
Accumulated Impairment Loss |
Net Carrying Amount |
||||||||||
Balance as of December 31, 2021 |
( |
) | ||||||||||
Acquisition of Safekeep, Inc. |
||||||||||||
Balance as of March 31, 2022 |
( |
) |
Estimated Useful Life (Years) |
Weighted- Average Remaining Useful Life (Years) |
Gross Carrying Amount |
Accumulated Amortization |
Net Carrying Amount |
||||||||||||||||
Customer relationships |
$ | $ | ( |
) | $ | |||||||||||||||
Acquired technologies |
( |
) | ||||||||||||||||||
Subtotal |
( |
) | ||||||||||||||||||
Trademarks—indefinite life |
— | |||||||||||||||||||
Total intangible assets |
$ | $ | ( |
) | $ | |||||||||||||||
Estimated Useful Life (Years) |
Weighted- Average Remaining Useful Life (Years) |
Gross Carrying Amount |
Accumulated Amortization |
Net Carrying Amount |
||||||||||||||||
Customer relationships |
$ | $ | ( |
) | $ | |||||||||||||||
Acquired technologies |
( |
) | ||||||||||||||||||
Favorable lease terms |
( |
) | ||||||||||||||||||
Subtotal |
( |
) | ||||||||||||||||||
Trademarks—indefinite life |
— | |||||||||||||||||||
Total intangible assets |
$ | $ | ( |
) | $ | |||||||||||||||
Years Ending December 31: |
||||
2021 |
$ | |||
2022 |
||||
2023 |
||||
2024 |
||||
2025 |
||||
Thereafter |
||||
Total |
$ | |||
13. |
ACCRUED EXPENSES |
March 31, 2022 |
December 31, 2021 |
|||||||
Compensation |
$ | $ | ||||||
Professional services |
||||||||
Software license agreement |
||||||||
Sales tax |
||||||||
Royalties and licenses |
||||||||
Employee insurance benefits |
||||||||
Other |
||||||||
Total |
$ | $ | ||||||
14. |
OTHER LIABILITIES |
March 31, 2022 |
December 31, 2021 |
|||||||
Software license agreement |
$ | $ | ||||||
Deferred revenue-non-current |
||||||||
Contingent consideration |
||||||||
Total |
$ | $ | ||||||
15. |
LONG-TERM DEBT |
(1) | a base rate determined by reference to the highest of (a) the rate last quoted by the Wall Street Journal as the “prime rate,” (b) the federal funds effective rate plus one-month LIBOR plus |
(2) | a Eurocurrency rate determined by reference to LIBOR (other than with respect to Euros, Euribor and with respect to British Pounds Sterling, SONIA) with a term as selected by the Company, of one, three or six months (subject to (x) in the case of term loans, a |
March 31, 2022 |
December 31, 2021 |
|||||||
Term B Loan |
$ | $ | ||||||
Term B Loan—discount |
( |
) | ( |
) | ||||
Term B Loan—deferred financing fees |
( |
) | ( |
) | ||||
Term B Loan—net of discount & fees |
||||||||
Less: Current portion |
( |
) | ( |
) | ||||
Total long-term debt—net of current portion |
$ | $ | ||||||
16. |
CAPITAL STOCK |
17. |
STOCK INCENTIVE PLANS |
Shares |
Weighted- Average Exercise Price |
Weighted- Average Remaining Contractual Life (in years) |
Aggregate Intrinsic Value (in thousands) |
|||||||||||||
Options outstanding—December 31, 2021 |
$ | $ | ||||||||||||||
Exercised |
( |
) | ||||||||||||||
Forfeited and canceled |
( |
) | ||||||||||||||
Options outstanding—March 31, 2022 |
$ | $ | ||||||||||||||
Options exercisable—March 31, 2022 |
$ | $ | ||||||||||||||
Options vested and expected to vest—March 31, 2022 |
$ | $ | ||||||||||||||
Expected term (in years) |
||||
Expected volatility |
% | |||
Expected dividend yield |
% | |||
Risk-free interest rate |
% | |||
Fair value at valuation date |
$ |
Shares |
Weighted- Average Fair Value |
|||||||
Non-vested RSUs—December 31, 2021 |
$ | |||||||
Granted |
||||||||
Vested |
( |
) | ||||||
Forfeited |
( |
) | ||||||
Non-vested RSUs—March 31, 2022 |
||||||||
For the Three Months Ended March 31, |
||||||||
2022 |
2021 |
|||||||
Cost of revenues |
$ | $ | ||||||
Research and development |
||||||||
Sales and marketing |
||||||||
General and administrative |
||||||||
Total stock-based compensation expense |
$ | $ | ||||||
18. |
WARRANTS |
• | at a price of $ |
• | upon a minimum of 30 days prior written notice of redemption to each warrant holder; and |
• | if, and only if, the closing price of the Company’s common shares equals or exceeds $18.00 per share (as adjusted) on the trading day prior to the date on which the Company sends the notice of redemption to the warrant holders. |
• | at a price of $ |
• | upon a minimum of 30 days prior written notice of redemption provided holders will be able to exercise their warrants on a “cashless basis” prior to redemption and receive that number of shares determined by reference to an agreed table based on the redemption date and the fair market value of the Company’s common stock; and |
• | if, and only if, the closing price of the Company’s common stock equals or exceeds $10.00 per share (as adjusted) on the trading day prior to the date on which the Company sends the notice of redemption to the warrant holders. |
19. |
COMMITMENTS |
20. |
LEGAL PROCEEDINGS AND CONTINGENCIES |
21. |
RELATED PARTIES |
22. |
NET INCOME (LOSS) PER SHARE |
For the Three Months Ended March 31, |
||||||||
2022 |
2021 |
|||||||
Numerator |
||||||||
Net income (loss) |
$ | $ | ( |
) | ||||
Denominator |
||||||||
Weighted average shares of common stock—basic |
||||||||
Dilutive effect of stock-based awards |
||||||||
Weighted average shares of common stock—diluted |
||||||||
Net income (loss) per share: |
||||||||
Basic |
$ | $ | ( |
) | ||||
Diluted |
$ | $ | ( |
) |
23. |
SEGMENT INFORMATION AND INFORMATION ABOUT GEOGRAPHIC AREAS |
For the Three Months Ended March 31, |
||||||||
2022 |
2021 |
|||||||
United States |
$ | $ | ||||||
China |
||||||||
Total revenues |
$ | $ | ||||||
March 31, 2022 |
December 31, 2021 |
|||||||
United States |
$ | $ | ||||||
China |
||||||||
Total software, equipment and property-net |
$ | $ | ||||||
24. |
GAIN ON SALE OF COST METHOD INVESTMENT |
25. |
SUBSEQUENT EVENTS |
Item 13. |
Other Expenses of Issuance and Distribution |
Amount Paid\ |
||||
SEC Registration Fee |
$ | 649,215.32 | ||
Printing |
125,000 | |||
Legal fees and expenses |
150,000 | |||
Accounting fees and expenses |
175,000 | |||
Miscellaneous expenses |
10,000 | |||
Total: |
$ | 1,109,215.32 |
Item 14. |
Indemnification of Directors and Officers. |
Item 15. |
Recent Sales of Unregistered Securities. |
Item 16. |
Exhibits and Financial Statement Schedules. |
Item 17. |
Undertakings. |
Item 16. |
Exhibits |
+ | Indicates a management or compensatory plan. |
† | Schedules to this exhibit have been omitted pursuant to Item 601(b)(2) of Registration S-K. The Registrant hereby agrees to furnish a copy of any omitted schedules to the Commission upon request. |
CCC Intelligent Solutions Holdings Inc. | ||
By: | /s/ Githesh Ramamurthy | |
Name: | Githesh Ramamurthy | |
Title: | Chief Executive Officer and Chairman of the Board of Directors |
Signature |
Title |
Date | ||
/s/ Githesh Ramamurthy Githesh Ramamurthy |
Chief Executive Officer and Chairman of the Board of Directors (Principal Executive Officer) |
June 7, 2022 | ||
/s/ Brian Herb Brian Herb |
Executive Vice President, Chief Financial and Administrative Officer (Principal Financial Officer) |
June 7, 2022 | ||
/s/ Rodney Christo Rodney Christo |
Chief Accounting Officer (Principal Accounting Officer) |
June 7, 2022 | ||
Steven G. Puccinelli |
Director | June 7, 2022 | ||
* William Ingram |
Director | June 7, 2022 | ||
* Eileen Schloss |
Director | June 7, 2022 | ||
* Teri Williams |
Director | June 7, 2022 | ||
* Christopher Egan |
Director | June 7, 2022 | ||
* Eric Wei |
Director | June 7, 2022 | ||
* Lauren Young |
Director | June 7, 2022 | ||
* /s/ Brian Herb Brian Herb Attorney-in-Fact |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the use in this Registration Statement No. 333-259142 on Form S-1 of our report dated March 1, 2022, relating to the consolidated financial statements of CCC Intelligent Solutions Holdings Inc. and subsidiaries. We also consent to the reference to us under the heading Experts in such Registration Statement.
/s/ Deloitte & Touche LLP
Chicago, IL
June 7, 2022